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ABSTRACT

Leukemia Stem Cells (LSCs) from Acute Myeloid Leukemia (AML) require the
activity of the transcription factor NF-κB to maintain stemness and drive tumor
formation. Blocking NF-κB can preferentially eliminate LSCs in vitro with minimal
effects on healthy Hematopoietic Stem and Progenitor Cells (HSPCs), making NF-κB a
compelling target for anti-leukemia therapies. However, blocking NF-κB in vivo can only
extend survival for a short period of time before transplanted mice succumb to the
disease. I propose this is due to components of the in vivo niche supporting LSC survival
and compensating for the inhibition of NF-κB.
I observed patients with partially differentiated blast-like AML (subtypes M3,
M4, and M5) have significantly elevated levels of pro-inflammatory cytokines TNFα and
IL-1α/β (TNF and IL1) circulating in their peripheral blood. Further study revealed these
cytokines are primarily produced by LSCs because such cells express several times more
of TNF and IL1 than their healthy tissue counterparts. I found that TNF and IL1 stimulate
the growth and expansion of LSCs while inducing cell death in HSPCs. Also, LSCconditioned media alone is sufficient to drive apoptosis/necroptosis in HSPCs that can be
prevented by blocking TNF and IL1, suggesting a mechanism for hematopoietic
repression commonly observed in AML cases.
TNF and IL1 drive their pro-inflammatory effects on target cells through
activation of cellular signaling networks. Both TNF and IL1 are potent activators of NF-

	
  

xiv	
  

κB in almost all cells studied, connecting the ability of these cytokines to drive LSC
growth with the need of NF-κB for survival. In addition, TNF and IL1 also stimulate
activation of JNK signaling which operates in parallel to NF-κB in LSCs and HSPCs. I
found that JNK stimulation results in cell death in HSPCs by subsequent inactivation of
pro-survival Bcl-2 family proteins by phosphorylation. However, LSCs convert JNKmediated cell death signals into proliferation/survival signals by both limiting the signal
duration to <60 min through dephosphorylation by Map Kinase Phosphatase 5, and also
by upregulating JNK’s nuclear target c-Jun. Such short duration of JNK activation
correlates to activation of JNK’s nuclear targets without activating the death signal.
I determined that concurrent inhibition of NF-κB and JNK has two major effects:
(1) combined inhibition specifically targets LSCs in vitro and in vivo, and (2) the toxicity
in healthy HSPCs due to loss of NF-κB signaling is mediated by JNK, making the
combined treatment protective. I can substantially increase survival in AML-transplanted
mice if they are treated with combination of NF-κB and JNK inhibition in vivo. I can
further extend survival in leukemic mice when I treat with blockers to upstream proinflammatory cytokines: anti-TNF, anti-IL1, and NF-κB inhibitor. These data provide a
strong rationale to treat AML patients by combined inhibition of both TNF/IL1- JNK and
NF-κB signaling.
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CHAPTER 1
INTRODUCTION
Leukemia Stem Cells (LSCs), like their healthy tissue counterparts, are a subset of
Leukemia Cells (LCs) capable of maintaining tumor homeostasis, are contextually
undifferentiated, and can remain in a relatively slow-cycling state until signaled to
proliferate. LSCs possess the ability to regenerate the leukemia tumor.1,2 While the
leukemic burden can be almost entirely eliminated (clinically: complete remission) in
most patients when treated with chemotherapeutic drugs, some LSCs remain due to their
intrinsic apoptosis resistance and niche-based protection. This renders these cells immune
to traditional chemotherapies, making these LSCs the population of cells widely
considered to be responsible for minimal residual disease (MRD) following therapy.3
Cells expanded from the LSCs retained in the MRD population are essentially preselected for chemotherapeutic resistance. Therefore, in order to eliminate MRD and
prevent relapse, we need to develop therapies that will target LSCs at the very core of
what makes a LSC a stem cell, not just reducing blast percentage by killing differentiated
progenitor and blast cells.4,5 If we could block the stem cell maintenance machinery
components from LSCs, then we should be able to more effectively reduce the risk of
disease relapse. My studies suggest I can accomplish this through manipulating proinflammatory signaling in the leukemic stem cell niche.
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All stem cells have a home, which is a specialized microenvironment called the
“niche.” The niche provides all the extrinsic support stem cells require to block
differentiation, ensure cell survival, and maintain self-renewal.6,7 LSCs also reside in a
niche, and although the LSC niche is located in the bone marrow along with the HSPC
niche, its microenvironment is fundamentally altered.8 Unlike the hematopoietic stem cell
(HSC) niche, the LSC niche is pro-inflammatory and does not sustain normal
hematopoiesis. This alteration is critical for sheltering LSCs from chemotherapy and
retaining the necessary stem cell maintenance processes.9 Identifying these and other key
differences between the healthy HSC niche microenvironment and the LSC niche
microenvironment will provide us with the necessary tools to block LSC functions while
protecting HSPCs.
A primary function of normal HSC niches is to protect the HSCs from excessive
inflammatory stimuli. By working with collaborators, we determined LSCs produce large
amounts of inflammatory cytokines, Tumor Necrosis Factor alpha (TNF) and Interleukin1 (IL-1), which they secrete into their niche. Normally, these inflammatory cytokines
induce differentiation, apoptosis and necroptosis in normal tissue cells.10,11 In AML
patients, elevated levels of TNF are associated with higher leukocyte counts, lower
complete remission rates, and poorer prognoses.12 I found that some patients with AML
have high levels of circulating TNF in their blood serum when compared to healthy
donors. While normal levels of TNF in healthy individuals with no major immune
activity should be approximately 12 pg/mL, I found some patients had circulating TNF as
high as 65 pg/mL. This indicates an acute induction of inflammatory reactions in the
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body. I measured serum of patients from the M2, M3, M4, and M5 subgroups of AML
and found the increase in circulating TNF was primarily in patients from M3 (APL), and
M4/5 (monocytic) AMLs (Figure 1A). Many cancer patients can exhibit inflammation
(elevated TNF, IL1, IL6, TGF-B) due to the massive amounts of cell death caused by
tumor formation and immune response or the effects of chemotherapy. Therefore I sought
to determine if the observed TNF levels were being produced by the tumor cells
themselves, or by macrophages/immune cells/stromal cells. To do this, I isolated AML
blasts (CD34+) from the peripheral blood of these patients and performed qRT-PCR
analysis to determine if TNF mRNA was being produced. I found that tumor cells from
these patients had a 5-6 fold increase in TNF production (Figure 1B). Large scale
analysis of samples from AML patients from collaborator at University of Chicago
corroborated this data, showing an increase in TNF and receptors in M3, M4, and MLLRearranged M5 AMLs (Figure 1C). This validates my selection of MLL-AF9 as a fusion
gene to transform my mouse leukemia cells because MLL-AF9 AMLs are characterized
as M4 and M5.
However, while we observed elevated TNF levels in these patients, we did not
understand the role TNF played in affecting LSC survival. To test this, I stimulated LCs
with an increasing gradient of exogenous recombinant Tnf, from levels resembling
normal physiological state (0.01 ng/mL) to acute inflammatory disease (50 ng/mL) and
measured colony formation. I found that this stimulation increased the colony formation
rate of LCs in a dose-dependent manner, while increasing doses of Tnf reduced the
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Figure 1. Several subtypes of AML produce TNF

A) TNF concentrations in peripheral blood of AML patients as shown by ELISA from
individual patient samples. B) TNF expression in LC isolated from individual AML
patient samples as shown by qRT-PCR assay. Horizontal bars in A and B indicate mean
levels. * indiciates p<0.05 as determined by students T test when compared to healthy
donor control. C) cDNA microarray analysis of TNF and TNF receptors (R1 and R2) in
AML patient samples. t(8:21), t(15:17), and inv(16) are AML subtypes M2, M3, and M4,
respectively. MLL leukemias include MLL-AF4 (B-ALL) and MLL-AF9 (AML-M5).
CD34+ HSPCs, CD33+ myeloid progenitors, and/or MNCs from healthy donors were
used as controls.
A and B were acquired by collaborators Drs. Jing Li and Xingyu Li at Shanghai Normal
University, while C was acquired from collaborator Dr. Jianjun Chen at University of
Chicago
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colony formation capacity of hematopoietic stem and progenitor cells (HSPCs, mixture of
HSC and progenitors). Tnfr-/- LCs deficient for both Tnf receptors (Tnfr1a/1b, Tnfr-/hereafter) were used as negative controls because they lack the Tnf receptors and should
not respond to Tnf stimulation (Figure 2A). Tnf receptor deletion was confirmed
genetically by PCR of tail cell DNA. Wild type and knockout alleles are denoted.
I then asked if the increase in colonies upon Tnf stimulation was directly Tnfdependent. To answer this, I grew LCs in suspension culture and treated with exogenous
Tnf every day for four days. I found that this treatment was able to significantly increase
the growth rate of LCs when compared to vehicle treated control cells as control. Tnfr-/LCs were also used as controls, and showed a reduced growth rate when compared to
their Tnfr+/+ (WT hereafter) counterparts (Figure 2B).
I determined LCs produce their own endogenous Tnf, and this endogenous Tnf
could affect the growth rate of WT LCs. To account for this, I treated LCs in suspension
culture with an anti-TNF monoclonal antibody (mAB) to neutralize soluble Tnf. This
treatment slowed the growth of the LCs to the rate of Tnfr-/- LCs, suggesting that the
higher rate of cell growth in WT LCs versus Tnfr-/- LCs is due to TNF (Figure 2C).
Vehicle treated LCs ,WT and Tnfr-/-, were used as controls. These TNF-expressing AMLs
were later found to be highly sensitive to NF-κB and JNK inhibition treatment (Figure
39). However, I found that some patient samples were sensitive to co-inhibition of NF-κB
and JNK, but did not express TNF (Figure 42). Therefore, I looked at other proinflammatory cytokine expression in AMLs using a large-scale microarray analysis of

	
  

	
  

Figure 2: TNF promotes LC growth

A) CFU from LCs and HSPCs were treated with indicated doses of Tnf in
methylcellulose. The numbers of CFU in each cell type in Tnf-treated groups were
normalized to CFU number in vehicle treated group. Genotype results are shown for WT
and Tnfr-/- LCs. B and C) LCs and Tnfr-/- LCs were treated with Tnf (B) or anti-TNF
mAB (C) in suspension culture daily for four days. Daily live cell counts were measured
by trypan blue exclusion assay. Values shown are mean ± SD from three independent
trials. * indicates p<0.05 when compared to vehicle treated control

	
  

6	
  

	
  

7	
  

Figure 3: Many different types of AML produce IL1 and TNF

A) 580 different human AML samples were analyzed by cDNA array for up and
downregulation of various factors compared to internal controls. Green indicates low
expression, red indicates high expression. Different AML subtypes are indicated. Genes
listed to the right of the vertical red bar are upregulated along with TNF in M4/5 AML.
B) Serum samples taken from newly diagnosed AML patients analyzed for TNF, IL1a,
and IL1B by ELSIA. HSPCs from healthy donors were used as negative controls.
C) Relative expression of mRNA levels compared to HSPC expression of TNF as
control. cDNA levels were normalized to GAPDH. * indicates p<0.05 when compared to
HSPC control as determined by one-way ANOVA with Bonferonni post-hoc test.
cDNA array data in A was generated by Dr. Jianjun Chen at University of Chicago.
Patient data from B and C was generated by Dr. Jing Li at Shanghai Normal University,
Shanghai, China.
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581 patients from a collaborator. I found that in addition to TNF, the same AML subtypes
that express TNF also expressed an additional pro-inflammatory cytokine, IL1α and IL1β
(IL1 hereafter) (Figure 3A). These patients expressed both cytokines in their peripheral
blood (Figure 3B), and the cytokine was determined to be coming from the leukemia
tumors (Figure 3C). To study the pro-survival effects of IL1 signaling in LCs and
HSPCs, I treated LCs and HSPCs in parallel with increasing doses of exogenous IL1, and
measured colony formation. I found that even with treatments at 1 ng/mL, colony
formation was significantly enhanced in both WT LCs and Tnfr-/- LCs. Further increases
in IL1 treatment concentration drove a dose-dependent CFU increase in both cell types.
This suggests that IL1 is operating as a Tnf-independent survival signal (Figure 4A).
Vehicle treated cells were used as controls. HSPC colony formation increased with the
dose of IL1 in a dose-dependent manner (Figure 4B). I thought this might be due to
enhanced colony formation of progenitor cells following IL1 stimulation, but that the
stem cells may be negatively affected.
To test this, I stimulated HSPCs ex vivo with two doses of IL1. If this treatment
affected HSPCs, then the treated cells would have impaired engraftment and
reconstitution of hematopoiesis in vivo. This turned out to be correct. HSPCs treated with
the low dose of IL1 had repressed ability to reconstitute lethally-irradiated mice when
compared to vehicle-treated control. High dose-treated HSPCs showed the lowest
reconstitution ability (Figure 4C). Vehicle-treated HSPCs were used as controls, and
exhibited stable reconstitution during the competitive transplantation assay.
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I determined that TNF drives a powerful survival signal that is augmented by IL1
signaling, operating in parallel. that functions parallel to NF-κB through activation of
JNK signaling. These pro-inflammatory cytokines function in an autocrine manner to
support LSC survival and self-renewal while also functioning in a paracrine manner to
induce apoptosis/necroptosis in neighboring HSPCs. This effectively clears HSPCs from
the LSC niche and may account for hematopoietic repression observed in AML patients.
I found that, conversely, blocking IL1 in LCs can repress colony formation.
Blocking IL1 and Tnf together was able to accomplish the largest amount of CFU
repression in LCs. This further confirms my hypothesis that LSCs use TNF and IL1 as
critical survival signals. They accomplished this by first treating LCs with an IL1
receptor antagonist to block IL1 in combination with a monoclonal antibody against Tnf.
They saw a dose-dependent decrease in CFUs with increasing doses of IL1 receptor
antagonist (IL-1Ra, Figure 5A). They confirmed this by performing similar experiments
in Tnfr1a-/-1b-/- (Tnfr-/- hereafter) LCs treated with an increasing dose of IL-1Ra and
found similar results, suggesting that these effects are specific (Figure 5B). Finally, they
confirmed the specificity of the IL-1Ra by knocking down the IL1 receptor by shRNA
(Figure 5C) and treating with anti-Tnf antibody, measuring CFUs. Vehicle treated cells
expressing a control shRNA were used as control (Figure 5D).
Based on these observations, I proposed that LSCs produce pro-inflammatory
cytokines in order to both promote their own survival and proliferation as well as repress
normal stem cell function.
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Figure 4. Exogenous IL1 enhances CFUs of LCs, promotes HSPC repression

A) WT and Tnfr-/- LCs were treated with indicated doses of exogenous IL1 in
methylcellulose, and colonies were counted seven days later. Vehicle-treated LCs of each
genotype were used as negative controls. Results shown are mean ± SD from three
independent trials. B) WT HSPCs were treated with indicated doses of IL1 in
methylcellulose, and colonies were counted ten days later. Vehicle-treated HSPCs were
used as negative controls. Results shown are mean ± SD from three independent trials.
C) CD45.1 HSPCs were treated ex vivo with indicated doses of IL1 and competitively
transplanted 1:1 with vehicle-treated CD45.2 HSPCs in lethally-irradiated recipient mice.
Chimerism was measured monthly. Results shown are mean ± SD from n=5 recipient
mice for each condition. * indicates p<0.05 as determined by one-way ANOVA with
Bonferonni post-hoc test.
These results were obtained by Dr. Jing Li at Shanghai Normal University, Shanghai,
China.
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LSCs are dependent on NF-κB, a transcription factor, for maintaining survival and selfrenewal.13,14 Blocking NF-κB in vitro can preferentially eliminate LSCs while having
minimal effects on HSPCs. This creates a promising target for anti-leukemia therapies.
However, in vivo NF-κB inhibition in leukemia-transplanted mice only minimally
extends their survival, suggesting that some component of the in vivo leukemic niche is
stimulating a compensatory survival signal to NF-κB. I determined that LSCs secrete
pro-inflammatory cytokines TNF and IL-1 into the niche microenvironment, reorganizing
the niche to support LSC survival and self-renewal. These cytokines are responsible for
stimulating NF-κB-independent survival signals mediated through the JNK-AP1 survival
pathway in LSCs and cell death in HSPCs through activation of the JNK-Bid/Bad/Bax
apoptosis pathway. By blocking TNF/IL-1-mediated JNK signaling, I can re-sensitize
LSCs to NF-κB inhibition in vivo, driving the disease into complete remission. The goal
of this project is to determine how to improve elimination of LSCs by adding to the
effects of NF-κB inhibition. In vivo experiments show NF-κB inhibition alone is
insufficient to clear LSCs. In fact, NF-κB inhibition in vivo can only extend the lifespan
of transplanted mice by <1 week. This is in stark contrast to the complete elimination of
LSCs in vitro with a similar treatment. I propose that LSCs can escape NF-κB inhibition
in vivo by utilizing TNF/IL1-dependent, NF-κB-independent survival signaling. I will
accomplish this goal by examining two aims (Figure 6).
In the first aim of this dissertation, I explored how LSCs escape the effects of NFκB inhibition in vivo through endogenously secreted TNF. In LCs, I found TNF acts as an
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Figure 5. Co-inhibition of Tnf and IL1 represses LC CFU ability

A) WT and Tnfr-/- LCs were treated in parallel with indicated doses of IL1 receptor
antagonist (IL-1Ra) in methylcellulose. Colonies were read seven days following
treatment. B) WT LCs were treated with anti-TNF and IL-1Ra alone or in combination in
methylcellulose. Colonies were read seven days following treatment. C) LCs were
transduced with shRNA-expressing retroviral vectors targeted to IL1 receptor.
Knockdown was confirmed by qRT-PCR analysis. D) IL-1 knockdown LCs were treated
with vehicle of anti-TNF and seeded for CFU assay in methylcellulose. * indicates
p<0.05 as determined by one-way ANOVA with Bonferonni post-hoc test. Results shown
are mean ± SD, and are indicative of three independent trials of experimental replicates.
These results were obtained by Dr. Jing Li at Shanghai Normal University, Shanghai,
China.
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autocrine survival signal by activation of JNK as a survival signal. They accomplish this
by strict regulation of JNK through TNF receptor endocytosis, MKP5-mediated
dephosphorylation of JNK, and upregulation of nuclear substrate c-Jun. All of these
factors contribute to allow LCs to escape TNF-mediated cell death and instead use the
cytokine as an autocrine survival and proliferation signal.
In the second aim of this dissertation, I explored how other pro-inflammatory
cytokines contribute to NF-κB-independent survival of LCs. I determined that TNF alone
did not explain the pro-inflammatory survival phenotype observed. Therefore I concluded
that there were additional pro-inflammatory cytokines secreted by LCs and used as
autocrine survival signals. I determined that LCs also secrete pro-inflammatory IL1, and
that IL1 signaling augments the TNF-mediated survival signal through weak activation of
similar pro-survival signaling molecules JNK, NF-κB, ERK, and c-JUN.
I conclude that by blocking both TNF and IL1 together in LSCs can I maximally
eliminate NF-κB-independent survival signaling. The inhibition of these proinflammatory cytokines might also assist in re-organizing the LSC niche in vivo to a state
that is more similar to the normal healthy homeostatic hematopoietic niche. Mice
xenografted with AML and treated with TNF and IL1 blockers are highly sensitive to
NF-κB inhibition, with complete disease remission in some mice.
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Figure 6. Flow chart diagram of dissertation specific aims.
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CHAPTER 2
LITERATURE REVIEW
Stem Cell Overview
Complex organisms are made up of many different tissues, all cooperating with
each other to carry out the everyday tissue demands of life. Each tissue, in turn, is made
up of many different cell types, all cooperating with each other to carry out the function
of the tissue. Each cell within the tissue originates from a common ancestor cell called a
“stem cell.” Stem cells are a special subset of cells found within each tissue that are
responsible for maintaining homeostasis and function of their tissue by (1) remaining
dormant until signaled to divide, and (2) differentiating into the appropriate types of cells.
These stimuli can include acute signals such as inflammation released during physical
trauma, which will stimulate stem cells residing in the bulge of the hair follicle in the
epidermis to differentiate into new melanocytes and keratinocytes to heal the wound, as
well as more long-term homeostasis signals such as the blood stem cells reacting to low
oxygen at high altitude by differentiating into large numbers of oxygen-carrying red
blood cells.15-18
Stem cells were first characterized in the early 1960’s as specialized cells called
“Hematopoietic Stem Cells,” that were located somewhere in the bone marrow, and were
capable of dividing and regenerating blood cells.19 Since then, scientists have found
similar types of cells in almost every major tissue in the body.20-23 These stem cells all
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share common features: they are undifferentiated, they remain quiescent until activated,
and they can differentiate into any cell type from their tissue upon proper stimulation.24,25
These cells are so powerful at tissue regeneration that, such as the case of hematopoietic
tissue, a small number of stem cells (< 30) are sufficient to completely repopulate the
tissue in mice.26 Stem cells process along a one-way path from a single undifferentiated
cell to a completely differentiated tissue effector cell in stages, from stem cell, to
progenitor cell, to committed progenitor (Figure 7). With each division, the progenitor
cells become slightly more differentiated. A fertilized oocyte called the zygote and their
early daughter cells (morulas stage) can generate, with enough divisions, every cell in the
body and the extraembryonic tissues (including the placenta). This type of cell is called
“totipotent.” The early embryonic (blastocyst stage) cells produced by totipotent stem
cells will form all somatic cells (ectoderm, endoderm and mesoderm) and germline cells
of the developing embryo. These cells care called pluripotent stem cells. Pluripotent cells
can form any cell of the embryo, but are not capable of creating the placenta. As the
pluripotent cells divide, they eventually create each tissue layer, and within it, each
individual tissue.27 While most cells will become mature differentiated effector cells, a
small subset of cells will retain some stemness and will maintain tissue homeostasis
throughout the life of the organism. These are called somatic stem cells or multi-potent
stem cells. With each division, these somatic stem cells will become partially more
differentiated, progressing from stem cell to multipotent progenitor cell, to common
progenitor cell, and finally to completely differentiated effector cell (Figure 7).
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Figure 7: Stem cell differentiation paradigm
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Hierarchy of stem cells (SCs) and their progeny: Multipotent progenitors (MPPs),
committed progenitors (CPs), and mature (M) cells.
Figure adapted from Breslin and Volk, et al. 2014.
The final type of stem cell is called the germ-line stem cell, and is responsible for
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When a stem cell is signaled to divide, there are three possible outcomes:
symmetric expansion (self-renewal expansion), asymmetric division (also known as selfrenewal maintenance), and symmetric differentiation. Each outcome is determined by
factors related to tissue homeostasis. Symmetric expansion is a situation in which a single
stem cell divides into two undifferentiated stem cells. This process is commonly seen in
situations calling for an increase in stem cell number and will continue until a sufficient
number of stem cells is reached, such as observed in the rapidly growing tissues of postnatal mammals, or in post-irradiated immune-depleted mice.28,29 Asymmetric division is a
process where one stem cell will divide and create a copy of itself and a multipotent
progenitor cell. The stem cell re-enters quiescence and the multipotent progenitor cell
goes on to divide into tissue-specific effector cells. This occurs in tissue homeostasis
where cell numbers are stable, and is widely considered the default program for stem cell
division.30-35 Symmetric differentiation is a process in which one stem cell divides and
differentiates into two multipotent progenitor cells without replenishing the lost stem cell.
This is useful if there are proportionally too many stem cells or if the demand for tissue
effector cells is especially high. However, this situation can also occur to the detriment of
the organism if the normal machinery for maintaining stem cells is somehow broken
(Figure 8).
Stem Cell Self-Renewal
Self-renewal is a cell-division process unique to stem cells, where one stem cell divides
to create a multipotent progenitor cell and another stem cell. Self-renewal allows for
tissue regeneration without exhausting the stem cell pool. There are three general
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Figure 8. Stem cell division and fate paradigms
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Undifferentiated stem cells (black filled circles) can divide through three different
programs. Symmetric differentiation produces two partially differentiated MPPs (white
circles, far left), asymmetric division produces one SC and one MPP (middle), and
symmetric expansion produces two SCs (far right).
The fate a stem cell undergoes upon stimulation is determined by a balance of cell
autonomous machinery, and is highly regulated (bottom).
Figure adapted from Breslin and Volk, et al. 2014.
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processes common to all self-renewing stem cells: (1) mechanisms that block
differentiation in order to maintain the undifferentiated state, (2) mechanisms that ensure
cell survival by blocking apoptosis and senescence, and (3) mechanisms to promote
proliferation during expansion and quiescence during maintenance (Figure 9).
There is a key core transcriptional network responsible for self-renewal in
pluripotent stem cells, such as embryonic stem (ES) cells and induced pluripotent stem
(iPS) cells. These factors are Oct4, Nanog, Klf2 and Sox2，which normally function as a
complex. These factors promote self-renewal by up-regulating proliferation/survival
genes and down-regulating a collection of genes involved in apoptosis, senescence, and
differentiation. In addition, these pluripotent factors also maintain their own levels by
binding to their regulatory region in an auto-regulatory manner. Furthermore, these
pluripotent factors can reset the epigenetic landscape in differentiated mature tissue cells,
play an indirect role in opening the regulatory region of self-renewal related genes
including themselves. Adding these factors in any mature effector cells can actually
reprogram and dedifferentiate those cells back to a pluripotent stem cell state. Such
reprogramed stem cells are called iPS cells.36-39
There is also a key core transcriptional network responsible for self-renewal in
each type of somatic multipotent stem cell. Such a core transcriptional network is formed
by tissue specific transcriptional factors， which ensure self-renewal by promoting
proliferation and blocking differentiation at same time preventing stress-related apoptosis
or senescence. Differentiation blockage has been determined to be one of the key
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Figure 9. Factors that drive stem cell self-renewal.

2. 3.

1.

1. Block differentiation;
2. Ensure cell survival (repress apoptosis
and senescence);
3. Promote proliferation (during expansion)
or keep quiescent (during maintenance).
In order to self-renew, stem cells need to block differentiation, ensure cell survival, and
promote proliferation/keep quiescent.
Figure adapted from Breslin and Volk, et al. 2014.
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mechanisms for stem cell self-renewal and such mechanism seems tissue specific. In
some tissues, comprised of only one cell type, blocking stem cell differentiation can be
achieved with few factors. For examples, BMP-Bam signal in Drosophila germline stem
cells and Notch-CSL signal in satellite muscle stem cells, are sufficient to block
differentiation and ensure self-renewal.40-47 However, some somatic stem cells reside in
tissues with diverse lineages of effector cells need (such as hematopoietic and nervous
systems), and the machinery to maintain the undifferentiated state is significantly more
complicated. Blocking differentiation appears to be the most important factor, though, in
maintaining adult tissue stem cell self-renewal.48-58 Multiple signals and factors are
normally involved in maintaining the undifferentiated state in stem cells. This might
explain why it is so difficult to expand hematopoietic and nerve stem cells in vitro; it
might also explain why so many self-renewal factors have been identified in these tissue
stem cells. However, there are many self-renewal factors are required for the self-renewal
of almost all types of tissue stem cells. For example, 1) Polycomb proteins Bmi1, EZH1
and EZH2 regulate self-renewal of stem cells by repressing P15-P16/P19/P21 -mediated
apoptosis and senescence; 59-69 2) HIF1α and the FoxO family of transcription factors
regulate self-renewal by preventing ROS-stress –induced cell cycle arrest and
apoptosis;70,71 3) many different tissue stem cells block intrinsic apoptosis through
upregulation of Bcl-2 and Bcl-xL, and c-FLIP to prevent extrinsic apoptosis
(Overexpression of such anti-apoptosis genes has been shown to actually increase the
stem cell pool in most tissues studied);72-76 4) Tissue stem cells also upregulate DNArepair proteins to prevent the accumulation of DNA damage;71,77,78 5) Many stem cells
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also express telomerase, a protein responsible for maintaining telomere length. With each
trip through the cell cycle, chromatid telomeres are shortened by 20-50 bp due to endreplication deficiency generated through subsequent divisions.79-84
Quiescence is a defining characteristic of adult tissue stem cells. They spend the
majority of their lives being quiescent, which is essentially a dormant state where they
are not actively dividing, and have a very low level of protein production. Both in vitro
and in vivo studies have shown stimulation of stem cells into rapid proliferation will
compromise self-renewal and ultimately exhaust the stem cell pool. This is likely due to
an inability to complete all tasks of the self-renewal machinery (DNA damage repair,
telomere lengthening, replacing chromatin modifications), and driving either
apoptosis/death of the stem cell or differentiation into an effector cell. In support of this,
almost all tissue stem cells are slow-cycling when they replicate.72,85-88 Some studies even
suggest slow cycling is one of the most important mechanisms utilized by adult stem cells
to retain multipotency and maintain self-renewal.89-92 The slow-dividing nature of stem
cells also allows for ample time between divisions to repair any accumulated DNA
damage before it can trigger the apoptosis machinery. Although these are all cell-intrinsic
mechanisms for maintaining self-renewal, stem cells grown outside of ideal environments
will still differentiate and eventually die. Stem cells require a special microenvironment
called a niche to properly maintain themselves and tissues.
Stem Cell Niche Overview
The stem cell niche is the home of the stem cell, and is composed of two major
components: stationary/cellular (support cells, extracellular matrix, contact-dependent
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signals), and secreted/extracellular (soluble cytokines, oxygen concentration, Figure 10).
This microenvironment is responsible for enriching the stem cell, and maintaining it in an
undifferentiated, multipotent state by promoting self-renewal, blocking differentiation
and preventing apoptosis/senescence.6,7 In fact, many tissues have two identified niches:
one a quiescent niche, and the other an active niche. Stem cells residing in the quiescent
niche tend to be dormant, but stem cells in the active niche tend to proliferate and readily
differentiate into mature effector cells upon induction. The dynamic state of stem cells
(quiescent vs. active) can be regulated by movement of the stem cells between the two
niches (Figure 11).93-95
The stationary components of the stem cell niche are specialized cells that anchor
stem cells through cadherins and integrins, and communicate self-renewal signals
through contact-dependent signaling molecules. Some of the best studied contactdependent niche signals include development-related factors such as Notch ligands,
Wnts, BMPs, membrane-bound Kit, and Hedgehog.96-102 Many of these factors are cell
surface mediated signals that can only operate in trans, suggesting that the stem cell must
be in direct contact with the niche cell to maintain undifferentiated state and promote
self-renewal. These contact-dependent signals also provide spatial context for mitotic
spindle alignment during replication. When the stem cell divides during self-renewal, one
cell will remain in contact with the niche and the other cell, not in contact with the niche,
will differentiate into a multipotent progenitor. In the Drosophila ovary, germ line stem
cells interact with cap cells (niche cells) via E-cadherins.103,104 The self-renewal signal is
augmented by a gradient of self-renewal mediating factors (produced by the cap cells)
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Figure 10. Proposed model for the cellular and non-cellular components of the stem
cell niche
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The stem cell niche is formed by stationary components which provide a stable physical
residence for the stem cells, together with other support cells, and extracellular
components. Based on the type of stationary component, cellular or noncellular, two
types of stem cell niche have been proposed. (a) The stationary components of the
cellular niche are specialized niche cells, and (b) the stationary component of the
noncellular niche is a specialized ECM called the basement membrane.
Figure adapted from Breslin and Volk et al. 2014.
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such as Unpaired and BMP. Disruption of E-cadherins in the germ line stem cells causes
detachment and chemotaxis away from the cap cell and cytokine gradient, and results in
differentiation due to loss of the self-renewal signal leading to eventual depletion of the
stem cell pool. SNO cells (Spindle shaped N-cadherin+ Osteoblastic) in the hematopoietic
niche express cell-membrane bound SCF, Jagged, and Angiopoietin-1, which work
together to restrict proliferation and maintain stemness.105-109 Studies in rat mammary
epithelial stem cells show deletion of integrin signaling between the stem cell and the
basement membrane (a specialized component of the extracellular matrix) causes
disorientation of the mitotic spindle resulting in loss of self-renewal during replication
and eventual depletion of the stem cell pool.110,111
In addition to stationary components of the stem cell niche, there are also support
cells that accompany the stem cell and provide support by augmenting the existing niche
signals. The support cells also play a role in effecting the migration and trafficking of
stem cells between quiescent and active niches. An example of such a cells is the CAR
cell (CXCL-12 Abundant Reticular) in the HSPC niche. These CAR cells secrete SDF
and IL6, which act as chemotractants for the HSPCs, drawing them strongly to the bone
marrow and increasing their affinity for the vascular niche. This cell is hypothesized to
chaperone HSPCs from the quiescent osteoblastic bone marrow niche to the active
vascular niche.105 In addition to CAR cells, two additional types of support cells have
been identified in the bone marrow niche: CD146+ osteoprogenitors and Nestin+
mesenchymal stem cells.112,113 HSPCs in the vascular niche are thought to be actively
cycling and producing progenitor
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Figure 11. Active and quiescent niches regulate stem cell self-renewal
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Figure adapted from Breslin and Volk, et al. 2014.
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cells. In the Drosophila ovary, the somatic stem cell is a support cell component of the
germline stem cell niche that produces progeny, migrates away from the cap cell (niche)
during development, and is always in contact with the germline stem cell. The somatic
stem cell produces progeny (some of which become more niche cells), and its direct
contact with the germline stem cell and progenitor cells is required for complete
differentiation and formation of functioning follicles.114-117
Some non-neural stem cell niches have been identified that have requisite
sympathetic nervous stimulation. In the HSPC niche, nonmyelinating schwann cells (part
of the nervous system) innervate the osteoblasts and stimulate them to provide critical
growth factors such as TGF-β and CXCL-12 which support the niche and promote stem
cell dormancy and self-renewal. Denervation of the hematopoietic niche causes a sharp
reduction in osteoblastic tendrils and mobilization of HSCs.118
The extracellular components of the stem cell niche are all the soluble factors
contained in the microenvironment, as well as some of the extracellular matrix
components responsible for orientation and location signaling during replication and selfrenewal. These components are frequently secreted by classic niche cells, but some are
long-distance paracrine signals produced from cells that are far away from the stem cell
niche or even delivered from the peripheral circulation.
The extracellular matrix (ECM) consists of a complex network of interlocking
molecules including glycosaminoglycans and hyaluronic acids, as well as proteins
including collagens, fibronectins, and laminins. These proteins are produced both by stem
cells and niche cells and immerse the stem cell in niche ECM-mediated signaling through
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surface receptors such as integrins and CD44.119-126 Focal adhesion signaling is critical
for directing stem cell migration and anchoring, while integrins are implicated in
correctly aligning the mitotic spindle during cell division, which is responsible for proper
cell polarity driving asymmetric self-renewal division.31,33,35
In addition to the extracellular matrix, there is a broad array of soluble cytokines
in the niche microenvironment. These cytokines are responsible for induction of
quiescence or proliferation, and self-renewal or differentiation. The HSPC niche is one of
the best studied models for soluble cytokine-mediated stem cell maintenance. Some
identified soluble factors responsible for maintaining quiescence and self-renewal are
thrombopoietin (TPO), SCF, and SDF1 in the bone marrow niche. Mice deficient in these
cytokines have stem cell activation and depletion as well as mobilization of stem cells
away from the niche microenvironment. Other cytokines are responsible for driving
differentiation in response to some tissue need, including IL6, IL3 and G-CSF. Most of
these niche factors drive critical survival machinery that prevents senescence or
apoptosis/necroptosis in response to inflammatory stimuli such as TNFα, IL1α/β, and
interferons.127-133
The role of oxygen is also well-understood in the stem cell niche. High oxygen
content, as seen near the vasculature, induces cell stress-driven stem cell proliferation and
differentiation. Low oxygen content supports low cell stress and quiescence.134-138 The
HSPC niche is thought to be composed of two separate niches (quiescent osteoblastic
niche, and active vascular niche), each with a different stem cell activity and ambient
oxygen level. The vascular niche is near the blood vessels, is highly perfused with fresh
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oxygen, and is the hypothesized location of actively dividing stem cells. The osteoblastic
niche is further away from the vasculature and has a lower oxygen content. Here, HSPCs
are not stressed by oxygen levels and remain quiescent. However, some studies also show
that the space between the vascular niche and the osteoblastic niche is only one cell-width
in distance, suggesting that these two may share the factors which regulating the dynamic
of quiescence and proliferation of stem cells.139
A dynamic balance of these cytokines exists in the stem cell niche, forcing any
external stimuli to overcome the quiescence and survival signals provided by the niche
before the stem cell exits and divides. This is how the niche can both promote stem cell
quiescence and self-renewal, yet at the same time provide the tissue with a steady source
of appropriate numbers of progenitor cells to maintain tissue homeostasis. Deviation from
these signals causes stem cells to either expand and become exhausted or divide
uncontrollably. If a mutation occurs during this cellular expansion that represses cell
death or further promotes cycling and accumulates more mutations (Figure 12).
Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is a diffuse tumor of malignantly transformed
blood stem and progenitor cells from the myeloid lineage. This tumor is composed of
partially differentiated non-functioning blast cells. There are many known transforming
events in AML, including point mutations and genetic deletions. While most AMLs are
karyotypically normal, some AMLs can have two chromosomes fused together, creating
a fusion gene. Fusion genes are formed when double strand break repair results in two
genes from different chromosomes being fused together, though deletions/inactive
	
  

31	
  

	
  

mutation of tumor suppressors and chromosome amplifications /active mutation of
oncogenes are also common. These types of leukemia are characterized by the cell type
in which the mutations occur. Acute Promyelocytic Leukemia (APL) is caused by a
fusion between PML-RARα. Other common fusion genes and their associated subtypes
are: RUNX1-ETO (M2 subtype of AML), and CBFb-MYH11 (M4 subtype of AML).
Other genetic abnormalities are also common in AMLs, including deletions on
chromosomes 5, 9, and 13, as well as trisomy of chromosomes 8 and 21. Overexpression
of fusion genes and deletions/triplications of these portions on chromosomes generates a
pro-survival bias for these cells, and promotes self-renewal and uncontrolled
proliferation. However, roughly half of AMLs are cytogenetically normal, meaning they
do not express any detectable fusion genes.140
AML has a distinct disease progression. The disease is diagnosed by bone marrow
samples containing > 30% leukemic blasts (FAB morphologic diagnosis and
classification), and characterized by flow cytometric analysis of cell surface proteins as
well as cytogenic techniques (molecular diagnosis and classification). AML prognosis is
highly dependent on age of onset, with 60-85% of patients <65 y.o.a. achieving complete
remission (as determined by <5% blasts in bone marrow) and 30% achieving long-term
survival (> 5 years following treatment). However, if the patient is >65 y.o.a., their
chance of achieving complete remission is 40-55% and only 10-20% achieve long-term
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Figure 12. Niche factors that regulate stem cell self-renewal.
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Figure adapted from Breslin and Volk, et al. 2014.
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survival. Clinical treatment of AML is often composed of a “7+3” regimen of seven days
of cytarabine plus three days of anthracycline treatments. This treatment protocol
eliminates blasts from the bone marrow and peripheral blood. Some patients also receive
a stem cell transplantation consolidation therapy following induction chemotherapy,
depending on the disease karyotype, prognosis, and age of onset. In late-stage AML, the
blast percentage is so high that the blood can no longer carry sufficient oxygen for proper
tissue function or platelets for hemostasis, rendering these patients hypoxemic and
coagulopathic.
AMLs are diagnosed and characterized within eight different subgroups,
according to the French-American-British (FAB) subtyping system, with increasing
integers indicating the level of relative maturation of the predominating blasts or the
predominating cytogenetic abnormality. M0 is observed as undifferentiated AML, M1 is
an AML with minimal maturation, M2 has evidence of maturation (40% of such AML
are caused by translocation of the RUNX1 and ETO genes). M3 is also known as Acute
Promyelocytic Leukemia (APL), >95% of M3 AML is caused by translocation and fusion
of the PML and RARα genes, and will be discussed in this review later. M4 is an acute
myelomonocytic leukemia. >30% is caused by fusion of CBFβ and MYH11 genes due to
inv(16). M5 is an acute monocytic leukemia and includes AMLs caused by fusion of the
MLL gene to partner genes (such as AF9 and ENL, although MLL fusions are also
detected in other AML subtypes as well as Acute Lymphoblastic Leukemias and Mixed
Lineage Leukemias), and M6 is a relatively rare occurrence of acute erythroid leukemia.
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M7 is an AML formed of predominantly transformed megakaryocytes (acute
megakaryocytic leukemia), and is also relatively rare.
Successful treatment options are limited for AML. There is currently only one
subtype of AML that can be reliably put into long-term remission: Acute Promyelocytic
Leukemia (APL), which is caused by chromosomal translocations between chromosomes
15 and 17 in myeloid progenitor cells, resulting in the fusion of two genes: PML and
RARα. This type of leukemia is successfully treated by a combination of All-Trans
Retinoic Acid (ATRA) and Arsenic Tri-oxide (AsO3). APL patients treated with ATRA
and AsO3 have a 95% long-term remission rate.141 Current consensus mechanism of such
treatment is AsO3 induces apoptosis and ATRA degrades the fusion gene protein product
and induces differentiation to functioning granulocytes.
However, there is always a small population of leukemic cells that can evade
induction/remission chemotherapy.142,143 Because these treatments cause selective
pressure on the AML cells, they will remove all the sensitive cells and leave behind any
cells that have some kind of mutation or dysregulated gene that allows them to survive.
As a result, any future treatment with similar drugs will be ineffective at removing this
disease. This phenomenon is the basis of resistance, and in cancer is called Minimal
Residual Disease (MRD). Cells from the MRD population are the primary reason for
relapse and the eventual death of the AML patient. Because leukemic MRD cells are
capable of repopulating the tumor after chemotherapy, it was commonly believed that
MRD cells are enriched “Leukemia Stem Cells” (LSCs).144
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Leukemia Stem Cells
An increasing body of evidence suggests that neoplastic cells found in many
tumor types are functionally heterogeneous in their ability to initiate tumor growth as
determined by in vivo transplantation in mouse models.1,2 This suggests that tumors, like
normal tissues, are composed of a heterogeneous hierarchy of different cell types, with
some cells able to produce more tumor cells (stem cells), and partial differentiated
progenitor and blast cells. These cancer stem cells share some characteristics of normal
tissue stem cells: they are slow dividing, relatively resistant to cell death, and can
maintain tumor homeostasis through differentiation into tumor progenitor cells. These
characteristics make cancer stem cells very difficult to treat because almost all
conventional chemotherapy drugs target actively dividing cells and induce cell death via
DNA damage. In addition, cancer stem cells might have powerful machinery in place to
prevent cell death and repair DNA damage.145-150
It is generally believed that cancer stem cells (CSCs) are initiated from tissue
stem cells which have self-renewal capacity. However, CSCs could also arise from
mutated versions of progenitor cells in any stage of differentiation if self-renewal ability
can be obtained.151-153 Genetic deletion of the APC gene in intestinal crypt stem cells
ultimately leads to expansion of the cell population into a malignant tumor and a variety
of intestinal cancers.154 These studies suggest a stem cell origin of CSCs. Committed
myeloid progenitors or granulocyte-macrophage progenitors from Bcr-Abl+ chronic
myeloid leukemia patients in blast crisis phase of the disease commonly express high
levels of active β-catenin and have self-renewal capability.155,156 Many leukemic fusion
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genes such as MLL-AF9 and MOZ-TIF2 can induce leukemia development from myeloid
progenitors. These studies suggest progenitor origin of CSCs. In certain cancers, genetic
mutations and niche signaling collaborate to induce the development of CSCs by
dedifferentiation. For example, chronic inflammation in the liver (due to viral infection or
cirrhosis) and colon induces a perpetual state of wound-healing and can lead to mutations
and activations of genes that can impart self-renewal and dedifferentiation in previously
terminally-differentiated hepatocytes and intestinal epithelia through genetic instability
and downregulation of tumor suppressor p53 (Figure 13).157-161
LSCs, like any other stem cell population, are a specialized set of cells that are
capable of regenerating a similar type of leukemia upon transplantation. They are able to
repopulate leukemia tumor in leukemia remission patients after withdrawing
chemotherapeutic drugs. LSCs are a fascinating cell type to study because they arise from
healthy blood stem and progenitor cells, and reside in the HSPC niche, but they hijack the
niche and secrete inflammatory factors that repress the healthy blood stem cells. LSCs
were first identified as lin-CD34+CD38- AML cells that could regenerate leukemias in
xenograft animal models.1,2,162,163
LSCs, like all other stem cells, require factors to promote self-renewal, block
differentiation, and prevent apoptosis/senescence. One of a well-studied self-renewal
factor in LSCs is the polycomb repressor complex component BMI-1, which is
responsible for repressing senescence and cell cycle inhibition genes p16Ink4a and P19Arf.
BMI-1 has been regulated by many different mechanisms, including
transcriptional, translational and post-translational. For example, a recent study suggests
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that BMI1 activity is negatively regulated by AKT phosphorylation at serine residues
251, 253, and 255. Such phosphorylation of BMI1 is linked to proliferation and
differentiation of LSCs, leading to reduction of the stem cell pool and regression of the
tumor.164
Activated β-catenin, through the Wnt signaling pathway, travels to the DNA and
forms trimeric complexes at the regulatory regions of proliferation and survival genes
with the AP1 family transcription factors Jun and Fos. Together, the expression of these
genes block senescence and maintain the undifferentiated status of LSCs.165 NF-kB is
another critical transcription factor required for maintaining LSC survival through the
upregulation of antiapoptotic genes like c-FLIP, Bcl-2, Bcl-xL, and anti-necroptotic
genes like cIAP1/2. Recent studies show that NF-κB is even required for function of
oncoproteins involved in MLL-rearranged AMLs, contributing to the building evidence
that NF-κB activity is critical for LSC function.13
Integrins have been recently identified as critical mediators of LSC survival and
self-renewal. LSCs deficient in integrin beta3 have defects in engraftment and survival
due to reduction in intracellular kinase SYK activity. This results in loss of powerful
antiapoptotic and dedifferentiation signals, and the exhaustion of the LSC pool.166
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Figure 13. Model for cancer stem cell development.
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NF-κB overview
Nuclear Factor kappa B (NF-κB) is a major mediator of immunity, inflammation,
tissue regeneration, and cancer signaling.167-169 It is a member of a transcription factor
family composed of many different subunits that form dimers and translocate to the
nucleus to drive target gene expression (Figure 14). Canonical NF-κB is comprised of
p65-RelA, c-Rel and P105/50-NF-κB1, while non-canonical NF-κB is comprised of
precursor p100/p52-NF-κB2 and Rel-B. Most studies identify canonical NF-κB for being
critical in maintaining LSC function in AML, while non-canonical NF-κB functions in
many types of B lymphocytic malignancies. In AML, NF-κB is primarily stimulated by
inflammatory cytokines like TNF and IL1, as well as by the toll-like receptor (TLR)
family responsible for detecting pathogen-associated molecular patterns (called PAMPs)
and tissue damage-associated molecular patterns (named DAMPs). The standard
paradigm for NF-κB activation begins with surface receptor activation (TNFr1/2, IL1r,
TLRs), and recruitment of scaffolding proteins (such as TRAF2/5) to the intracellular
portion of the receptor. These scaffolding proteins are poly-ubiquinated by E3 ubiquitin
ligases in the cIAP family to form K63 type of poly-ubiquitin chains. Both TAB2/TAK1
and IKK (containing IKKα/β/γ) complexes are recruited to these chains, where TAK1 is
activated by an auto-phosphorylation mechanism which in turn activates the IKK
complex by phosphorylating IKKβ. IκBα’s function is to bind NF-κB and obscure the
nuclear localization signal, effectively sequestering NF-κB in the cytoplasm. After
phosphorylation, IκBα is polyubiquinated (K48 type) and targeted for destruction by the
proteasome.170 This interaction is so strong that NF-κB can be artificially blocked by
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overexpression of a super repressor mutation of IκBα (IκBαSR), which has both IKK
phosphorylation serine sites mutated to alanine.
NF-κB, once freed from the IκBα suppressor protein, translocates to the nucleus
to activate target genes. The transactivation domain of the NF-κB protein binds to other
NF-κB subunits, and travels to specific sequences in the promoter regions of target genes,
where the DNA-binding domain of the two subunits interacts with regulatory regions of
target genes, most of which happen to be Bcl-2 family proteins, c-FLIP antiapoptotic
proteins, or TNF family inflammatory proteins. The cellular signaling results of NF-κBactivated gene products are complex, because NF-κB can activate both pro-apoptotic
inflammatory cytokines and anti-apoptotic proteins. Pro-inflammatory cytokines induce
NF-κB activity, and NF-κB induces pro-inflammatory cytokine production, resulting in a
feed-forward loop or induces expression of negative regulator of NF-κB (such as IκBα
and A20) to turn off signal in a feed-back loop. This results in a cycle of NF-κB activity
upon stimulation with Tnf, as observed in mouse embryonic fibroblasts, of peaks every
30-60 minutes. This is attributed to the degradation and replenishment of IκBα repressor
subunits.171
Healthy HSPCs have a low level of NF-κB activity, making them prone to
destruction by inflammatory cytokine stimulation. Although these pro-inflammatory
cytokines can induce a low-level of NF-κB, it is not enough to overcome the proapoptotic/necroptotic signals imparted by these cytokines. LSCs, on the other hand, have
a very high basal level of NF-κB activity, rendering them mostly immune to
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Figure 14. Activation paradigm of NF-κB.
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any cell death mediated by inflammatory cytokine stimulation, while capitalizing on the
pro-survival and proliferative effects of NF-κB.172
These characteristics of NF-κB make it an attractive target for many different
types of cancers with elevated NF-κB activity. In fact, several in vitro studies show that
NF-κB activity is critical for maintaining LSCs. Inhibition of NF-κB activity can
completely eliminate LSCs in vitro before toxicity is seen in healthy HSPCs.14 However,
because NF-κB mediates a powerful anti-apoptotic signal in most tissues studied through
upregulation of several different families of survival genes, generating a clinicallyeffective inhibitor is challenging.4,5,173 The best molecules available for clinical inhibition
focus on either blocking IKK activity or preventing degradation of the IκBα repressor
subunit through proteasome inhibitors.3,5,174 These treatments have been approved and are
standard of care for some cancers like Multiple Myeloma. In AML, the observed effects
of NF-κB inhibition in vitro appear to vanish in vivo, suggesting that there are additional
signaling pathways activated in vivo that can compensate for NF-κB inhibition in LSCs. I
propose that these signals are provided by the LSC niche.
Leukemia Stem Cell Niche
AML patients often have repressed hematopoiesis. In my studies, I found that
patients with AML have significantly elevated serum levels of inflammatory cytokines
circulating in their peripheral blood, and that these inflammatory cytokines are being
produced by the leukemia cells. These inflammatory cytokines act in a paracrine manner
to induce cell death in neighboring HSPCs, and act in an autocrine manner to drive
survival and proliferation in the LSCs.172 Additionally, many of the standard-of-care
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chemotherapies are designed to induce apoptosis and necroptosis in rapidly dividing
leukemic blast cells. Ours and other’s studies suggest the LSCs are resistant to these
therapies because they change the healthy HSPC niche into a leukemia promoting
environment.
The dependence of a niche for the growth of disease stem cells is well
demonstrated in a pre-leukemic neoplasm called Myelodysplastic Syndrome (MDS).
MDS cells are a myeloid neoplasm that reconfigure the bone marrow niche, ultimately
displacing and rendering ineffective the resident HSPCs. MDS is characterized by
refractory anemia due to insufficient bone marrow hematopoiesis. Approximately 10% of
MDS patients progress to leukemia due to the expansion of mutant blasts. In in vivo
murine studies, MDS cells isolated from patients cannot be xenografted into mice without
concurrent transplantation of mesenchymal stromal stem cells from the same patient.
These studies suggest that the disease mesenchymal stem cells promote MDS stem cell
self-renewal through activated secretion of niche factors such as N-cadherin, IGFBP2,
VEGFA, and LIF. Without MDS mesenchymal stromal cells, MDS stem cells are unable
to engraft in recipients, suggesting these stromal cells are a critical component of the
CSC niche.175
LSCs reorganize the hematopoietic stem cell niche
LSCs utilize a complex signaling network to integrate various survival and selfrenewal signals from the niche in order to promote their own survival, self- renewal, and
block differentiation. Many of these self-renewal factors are similar to common stem cell
self-renewal factors (i.e. Bmi1, Wnt/B-catenin, SCF, and Bcl-xL). In fact, LSCs can
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secrete the chemotractant SCF that can attract both LSCs and healthy HSPCs to the
malignant LSC niche. This causes death and repression of the HSPC population in
patients, which can be reversed by inhibition of LSC-secreted SCF.176 Osteopontin
(OPN), a cytokine secreted by osteoblasts in the bone marrow, also acts as a
chemotractant to anchor blood stem cells in the niche. While this is advantageous for
maintaining HSPCs, LSCs also utilize OPN as a pro-survival/self-renewal signal.
Following cytotoxic chemotherapy, LSCs retreat to the OPN-rich HSPC niche, where
OPN induces quiescence and apoptosis-resistance. Blocking OPN in this system induces
proliferation and detachment from the niche, and can synergize with cytotoxic
chemotherapies.177 Additionally, LSCs have the ability to change the HSPC niche
microenvironment through secretion of pro-inflammatory cytokines and conversion of
vascular endothelia into vascular tissue-associated AML cells and mesenchymal stromal
cells (MSCs) into Cancer-Associated Fibroblasts (CAFs). This pro-inflammatory
microenvironment is toxic to healthy HSCs.
MSCs and vascular endothelia support LSCs in the reorganized niche
LSCs also have been shown to localize to the vascular hematopoietic niche, due to
their innate ability to survive in an oxygen-reactive environment.178 They accomplish this
by converting neighboring vascular endothelia cells into vascular tissue-associated AML
cells through the upregulation of V-CAM and CD105. Through this mechanism, LSCs
recreate the vascular niche into a supportive microenvironment. It should be noted that
LSCs have also been identified outside of the bone marrow niche and in the peripheral
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blood and spleen, suggesting that LSCs have the ability to survive and self-renew outside
of the niche.
Following therapies, LSCs can also induce local MSCs to form Nestin+ CAFs.
CAFs are characterized as large, spindle-shaped mesenchymal cells that are
characteristically similar to fibroblasts.179,180 In leukemias, studies suggest that LSCs
secrete pro-inflammatory cytokines which recruit Nestin+ MSCs to the leukemic niche
and differentiate them into CAFs. These CAFs then support the LSCs by
secretion/surface expression of additional pro-inflammatory and LSC-supportive
molecules such as TGF-β, Wnt, and Notch.180,181
By inducing local MSCs to become CAFs cells, LSCs convert the lowoxygen/non-inflammatory healthy hematopoietic niche into a malignant/highoxygen/pro-inflammatory leukemic niche. This leukemic niche promotes the survival of
LSCs in the presence of cytotoxic chemotherapies. Therefore, treatments are needed that
can evict LSCs from the niche and restore the niche to its original healthy form. Some
studies in mice suggest that displacing the LSCs from their niche can accomplish such a
task, and allow for repopulation with healthy HSPCs and long term remission from the
disease.182 Making the leukemic niche inhospitable to LSCs is the focus of our studies in
this dissertation, and represents the leading solutions for removing LSCs, MRD, and
providing AML patients with true long-term remission.
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Pro-inflammatory cytokines support LSCs in the reorganized niche
Pro-inflammatory cytokines act in a paracrine manner to induce cell death and
differentiation in healthy HSPCs, effectively clearing the niche for expansion and
colonization by LSCs. The LSCs also have mechanisms in place to convert the usual
death signals from the pro-inflammatory cytokines into survival signals. This way, the
pro-inflammatory cytokines can act in an autocrine manner to drive survival and selfrenewal of the LSC. Some of these critical factors in leukemogenesis are IL6, IL3, TNF,
and IL1.
IL6 is one of the major pro-inflammatory cytokines secreted by immune cells in
the body. IL6 stimulation normally drives multipotent progenitor cell differentiation into
the granulocyte lineage. In Bcr-Abl chronic myeloid leukemia (CML), the blast cells
secrete pro-inflammatory IL6 to reorganize the niche in order to promote survival and
proliferation of CML stem cells. CML stem cells are different from the differentiated
CML blasts in that they are tyrosine kinase inhibitor resistant.183,184 Although seemingly
independent of tyrosine kinase activity, these CML stem cells appear to be dependent on
a positive feed-forward loop revolving around IL6 secreted by granulocytes for survival
and proliferation. CML blasts secrete IL6, which drives multipotent progenitor cells
towards the granulocyte/macrophage lineage and inhibits other lineage differentiation.
IL6 drives the proliferation of CML progenitors into leukemic granulocytes, which in
turn, produce more IL6, thus continuing the process. This process has been implicated as
a critical component for driving Bcr-Abl fusion leukemias.185
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IL3 is another pro-inflammatory cytokine secreted by activated T and mast cells,
and is implicated in LSC self-renewal. IL3 receptor, CD123 (IL3 α-subunit), is
overexpressed on LSCs and progenitors, and clinically correlates with lower survival and
poor prognosis in AML patients.186,187 Inhibition of the IL3 signal has been shown to
block survival/proliferation and homing of LSCs to their niche, as well as induces an
immune reaction against the LSCs, making targeting the IL3 receptor an interesting
therapeutic strategy for LSC-specific treatments. Several groups are currently working on
IL3-mediated therapies by develop anti-CD123 antibody or chimeric antigen receptor T
cells specific for CD123.188-190
TNF is a pleiotropic cytokine that induces a variety of cellular responses,
including cell survival, proliferation, and inflammatory cytokine production. TNF can
also stimulate both survival and death signals within the same cell, depending on the
context. TNF-stimulated survival is mainly mediated by formation of a complex that
consists of TRADD, TRAF2/5, cIAP1/2 and RIP1 (Complex I). TNF induces activation
of its receptors, TNFR1 and/or R2, stimulating Complex I formation. Complex I induces
the activation of TAK1 (a member of the MAP3K family of enzymes) through a K63linked polyubiquitin-dependent mechanism.191-202 TAK1 then induces the activation of
downstream signaling pathways, including IKK-IκB-NF-κB, MKK4/7-JNK-AP1 and
MKK3/6-p38.192,203-209 Activation of IKK-IκB-NF-κB signaling pathway protects the cell
from apoptosis/necroptosis by inducing expression of survival genes (Bcl2, Bcl-xl, Mcl1,
Survivin, cIAP1/2, and cFLIP).192,203-206,210-214 MKK3/6-p38 signaling will not be
discussed here because I found that inactive p38 promotes the colony-forming ability of
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both normal hematopoietic stem/progenitor cells (HSPCs) and MLL-AF9-transduced
murine LCs.
The TNF-induced death signal is mediated by the apoptotic complex (Complex II),
a necroptotic complex (necrosome) or a ROS production-related complex.215-230
Apoptotic Complex-II consists of RIP1/FADD/Caspase-8/cFLIP.215,216,220-230 FADD is a
scaffolding protein required for efficient TNF-induced caspase-8 activation, while cFLIP
is a caspase-8 homologue that negatively regulates caspase-8 activity by forming a
catalytically inactive heterodimer with caspase-8.215,216,231-235 The necroptotic complex
contains RIP1/RIP3 and induces cellular necroptosis through a mechanism that is
currently not understood.227-229,236-238 Recent studies suggest that the apoptotic and
necroptotic signals are dependent on each other: they form another complex called the
Ripoptosome

which

contains

both

Complex

II

and

the

Necrosome

(RIP1/RIP3/MLKL).236 Activated caspase-8 (Complex II) inhibits necroptosis by
inducing the cleavage of RIP1/RIP3. Thus upon ripoptosome formation, whether the cell
undergoes apoptosis or necroptosis is determined by the level of enzymatic activity of
Caspase-8.215,216,220,231,239

TNF

can

also

induce

the

formation

of

a

TRADD/RIP1/NOX1/RAC1 complex which leads to an increase in ROS production and
JNK signal-mediated cell death.240 The role of JNK in caspase-8-mediated apoptosis and
RIP3-mediated necroptosis is still a mystery.
Our lab found that TNF stimulates distinct signals in HSPCs and LCs. In HSPCs, in
addition to NF-κB-mediated survival signaling, TNF induces two parallel death signals:
JNK/RIP1/RIP3-dependent
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apoptosis.241 TNF-induced necroptosis can be prevented by treatment with Necrostatin-1
(Nec1, a RIP1 inhibitor) or RIP3 deletion, whereas TNF-stimulated apoptosis can be
repressed by JNK1 inactivation or Bcl2 over-expression and can be converted to
necroptosis by caspase-8 inhibition. The remaining HSPCs seem resistant to TNF
treatment. In LCs, JNK signal promotes survival/proliferation.
TNF and Acute Myeloid Leukemia
TNF is significantly increased in most tumor tissues, being produced by both
tumor cells and tumor-infiltrating hematopoietic cells.242-245 Early studies suggested that
TNF suppresses tumor activity by inducing apoptosis and/or necroptosis in tumor
cells.246-249 However, most cancer cells are resistant to TNF-induced death
signaling.246,247,250 Animal model studies suggested a tumor-promoting activity for
TNF.251-255 JNK-AP1 signaling induced by TNF plays an essential role in carcinogeninduced skin, liver and colon cancers.256-264 Inhibition of TNF signaling using soluble
receptors and neutralizing antibodies has become a potential treatment for some
malignancies. In fact, TNF blockers are currently standard of care for multiple
myeloma.265
In hematopoietic tissues, TNF-represses normal hematopoiesis by inducing death
signals in HSPCs. Increased TNF levels were detected in patients with bone marrow
failure, including aplastic anemia and myelodysplastic syndromes (MDS), suggests that
such hematopoietic repressive activity of TNF might contribute to the cytopenic
phenotype of these patients.143,266-275 The further increase in TNF levels during disease
progression in MDS patients implies that TNF might be involved in leukemic
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transformation of the mutant HSPCs and disease progression.271,276-278 In support of this
notion, TNF promotes the clonal evolution of leukemic cells in FancC-mutant HSPCs.279
Increased levels of TNF are detected in the PB and BM of most human leukemia patients
and are correlated to higher WBC counts and poorer prognosis.12 Our studies suggest that
TNF promotes LC growth in vitro and leukemogenesis in vivo. Inactivation of TNF can
inhibit the colonigenic growth of TNF-expressing LCs in vitro and repress leukemia
development in transplanted mice.172
IL1α/β (IL1) is another pleiotropic pro-inflammatory cytokine that has similar
pro-survival/pro-death activity as TNF. IL1, like TNF, is initially produced as a proenzyme in most leukocytes and endothelial cells, and is responsible for initiating
canonical inflammatory response pathways in most cells studied. IL1 pro-enzyme is
cleaved by catalytically active Caspase-1, which is only rendered functional after
stimulation of the NLRP1 inflammasome. This protein complex is normally activated by
interferon stimulation, IL1/TNF receptor activation, or toll-like receptor activation.
These inflammatory factors (and others from different cancers: IL-23, VEGF-A, CSF-1,
S100A8/9, TGF-B, and lysyl oxidase) are produced by LSCs and surrounding
stromal/epithelial/immune cells and act not just as chemotractants for cancer stem cells,
but also for formation of myeloid derived suppressor cells (MDSCs) that can
downregulate immune surveillance.242,280-284 MDSCs accomplish this by inhibiting both
adaptive and innate anti-tumor immunity. In the tumor stem cell niche microenvironment,

	
  

	
  

Figure 15. Pleiotropic effects of TNF stimulation on target cells.
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hypoxia alters the MDSC function and drives differentiation towards Tumor-Associated
Macrophages (TAMs) through activation of Hif1-α. TAMs can also differentiate from
normal healthy monocytes, and have a higher immuno-suppressive capability than
MDSCs by blocking T and NK-cell mediated tumor surveillance. TAMs also secrete
large amounts of pro-inflammatory cytokines IL-1β, TNF, IL4, and IL6, all of which
promote the expansion of LSCs while repressing normal healthy HSPC survival and selfrenewal.144
LSC self-renewal
LSCs employ many of the same components of the self-renewal machinery that
normal tissue stem cells utilize, and use them in a similar manner. This includes cell
cycle regulation and anti-senescence machinery like Bmi1, differentiation and lineage
control proteins like Wnt/β-catenin, and survival machinery like Bcl-xL and c-FLIP.
LSCs from MLL-rearranged leukemias also require other genes from the homeobox
group (Hox genes) to maintain self-renewal. In fact, simple over-expression of Hoxa9 in
hematopoietic progenitor cells from mice is sufficient to generate leukemia.285
Jun N-terminal Kinase (JNK) is one of the major mediators of leukemogenesis in
several models studied. In Fancc-knockout mice, TNF and JNK are required for clonal
evolution of the disease, and these animals develop leukemia in a JNK-dependent
manner.279 In Bcr-Abl-induced CML, TNF-induced JNK1 signaling is required for
activation of critical survival genes.286 This is in contrast to its most well-known role of
activating cell death via the intrinsic/mitochondrial apoptosis pathway. Other known
pathways requiring JNK activity for survival and proliferation is the complimentary
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proliferation response in hepatocytes following resection of a portion or
chemical/inflammation induced damage of the liver.287-289 Under this condition,
TNF/JNK signaling causes the death of a large number of hepatocytes, but stimulates
others to reform the tissue, while NF-κB acts as a tumor suppressor by repressing TNFJNK activity.290 TNF/JNK also promotes a proliferative signal in epidermal cells by
upregulating the positive regulator of cell cycle CDK4 and downregulating negative cell
cycle regulators like P16Ink4a.289,291 These signals are required for epidermal neoplasias
following NF-κB inhibition.
The most well-studied target of JNK is the transcription factor c-Jun. JNK
phosphorylates c-Jun at the N-terminus (hence its name: Jun N-terminal Kinase).
Phosphorylation by JNK causes c-Jun to form a dimer with either a member of the Fos
family (c-Fos, FosB, and splice variants Fra-1 and Fra-2), or another member of the Jun
family (JunB, Jun D). Together, this dimer is called AP1, and translocates to the nucleus
to act as an activator of target genes along with other transcription factors from the LEF
and β-Catenin family. Many genes are regulated by c-Jun including Myc/Myb, NF-κB
family proteins, and CD42, to name a few (Figure 16).
JNKs are members of the MAPK family variant called SAPK (stress-activated
protein kinases). Three isoforms are known: JNK1, 2 and 3. JNK1 and JNK2 are
ubiquitously expressed while JNK3 is primarily expressed in neuronal and heart tissues.
Like other MAPK family members, JNK is activated by a MAP3K-MAP2K-MAPK
three-component complex signal cascade. So far, More than 14 MAP3Ks for the JNK
signal have been identified (Figure 16).208,292-295 Although the physiological relevance of
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MAP3Ks in JNK activation has yet to be determined, some studies suggest that different
MAP3Ks might stimulate different levels and duration of JNK, generating different
biologic functions.296-298
Both pro-apoptotic and pro-survival/proliferative activities for JNK signal have
been reported. In many types of cells, upon TNF stimulation, JNK promotes a
mitochondrion-dependent cell apoptosis by phosphorylation-dependent inactivation of
several pro-survival Bcl-2 family members, or phosphorylation-dependent activation of
the pro-apoptotic BH3-only subgroup of the Bcl2 family of proteins.11,299-305 JNK also
induces the cleavage of Bid to a specific fragment termed “jBid”, and up-regulates proapoptotic genes such as Puma and Bax (Figure 2). The relationship between JNK and
Caspase-8 in apoptosis as well as the relationship of JNK and RIP1/3 to necroptosis
remain to be determined. Some studies suggested that Caspase-8 can function upstream
of JNK. However, in many types of cells, JNK induces apoptosis through stimulating
Caspase-8 activity by inducing the degradation of cFLIP, the key negative regulator of
Caspase-8, through the proteosomal degradation pathway. This is accomplished by
phosphorylating the E3 ubiquitin ligase responsible for marking cFLIP for degradation by
polyubiquitination, ITCH.306
The pro-survival and proliferative activities of the JNK signal are mediated by
transcriptional mechanisms. Several transcription factors, including AP-1 (cJun, ATF2,
JunD, JunB, cFos), Elk-1, c-Myc, NFAT4, HSF-1, androgen receptor, RXRα and RARα,
have been identified as nuclear substrates of JNK. AP-1 is the key transcriptional
regulator of JNK signaling, regulating the expression of survival and proliferation-related
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genes including c-Jun, cyclin D, c-Myc, ATF2, JunD and JunB.307,308 Despite intensive
study, the molecular mechanism by which JNK determines which pathway to activate
(apoptosis or survival/proliferation) is still largely unknown.
JNK Signaling and Leukemia Development

Sustained JNK activation has been reported in many types of AML.309 It was found
that JNK-AP1 signaling coordinates with AKT/FOXO signaling in maintaining AML
cells in an undifferentiated state.309 In a Bcr-Abl-induced leukemia/lymphoma model,
JNK1-AP1 signaling is activated by the fusion enzyme, and is required for leukemia
development by mediating a key survival signal.310 In Fanconi’s anemia, JNK is required
for TNF-induced leukemic clone evolution of FancC-mutant HSPCs.279,311 These studies
suggested that the JNK signal promotes leukemia development and progression by
inducing proliferation and survival activities. Thus, this signal could be a potential target
for anti-leukemia therapy. However, several previous studies suggested that JNK might
mediate cell death signaling induced by chemotherapeutic drugs such as arsenic trioxide
and some other agents in certain leukemic cells. These studies suggested that inhibition of
JNK might result in drug-resistance.312-315 However, these studies are mainly based on
evaluating the ratio of dead cells after short-term treatment. I found that inhibition of
JNK can significantly sensitize TNF-expressing LCs to the toxicity of several
chemotherapeutic drugs and NF-κB inhibitors with fewer effects on non-TNF-expressing
LCs, as shown by colonigenic assays.172 I propose that JNK inhibition might attenuate the
acute cytotoxicity of chemotherapeutic drugs and NF-κB inhibitors on partially

	
  

	
  

differentiated non-colonigenic LCs but promote the elimination of undifferentiated
colonigenic LCs (enriched with leukemic progenitors and LSCs).
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Figure 16. JNK is stimulated by upstream factors to drive downstream responses.

Growth factors, Cytokines, Stress stimuli

MEKK1, MEKK2, MEKK4,
MLK1, MLK2, MLK3, MLK4
DLK, ASK1, LZK1, TAK1,
TAO1, TAO2, ZAK

jBid

MKK4, MKK7

p

MKP-1

Senescence

P53

p

Bim Bmf

JNK1, JNK2, JNK3

p p

Bad
p

Itch

C-Jun, JunB, JunD, ATF2, ATF3,
Elk-1, Elk-3, p53, RXRα, RARβ,
AR, NFAT4, HSF-1 and c-Myc

Proliferation

Survival

Bax and PUMA

apoptosis

C-Jun, JunB, JunD and Fos

	
  

p

cFLIP

p p

Bcl2
p p

Bcl-xl
TNF

p

Mcl1

apoptosis

p

14-3-3

Bax
BaK

	
  
	
  

CHAPTER 3
METHODS
Mice and genotyping
All experiments using mice were performed according to the guidelines of Loyola
University Medical Center and were approved by the Loyola University Institutional
Animal Care and Use Committee. Tnfr1-/-2-/- mice (B6.129S-Tnfrsf1aTnfrsf1b) were
purchased from the Jackson Laboratory. BM hematopoietic cells from Rip3-/- (Rip3knockout) mice were provided by Dr. Vishva M. Dixit of the Department of
Immunology, Genentech, 1 DNA Way, South San Francisco, California 94080, USA.
Genotypes of all mice were determined by PCR assay using primers listed below (5’-3’):
Tnfr1-1

GGATTGTCACGGTGCCGTTGAAG

WT = 120 bp

Tnfr1-2

TGACAAGGACACGGTGTGTGGC

Mut = 155 bp

Tnfr1-3

TGCTGATGGGGATACATCCATC

Tnfr1-4

CCGGTGGATGTGGAATGTGTG

Tnfr2-1

CCGGTGGATGTGGAATGTGTG

WT = 257 bp

Tnfr2-2

AGAGCTCCAGGCACAAGGGC

Mut = 160 bp

Tnfr2-3

AACGGGCCAGACCTCGGGT

Rip3-1

GGCTTTCATTGTGGAGGTAAGCTGAGA

WT = 280 bp

Rip3-2

GAACCCGTGGATAAGTGCACTTGAAT

Mut = 320 bp
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Generation of murine leukemia cell lines:
CD117+ HSPCs were isolated from wild-type (WT), Tnfr-/- (knockout of both Tnfr
1 and 2), and Rip3-/- mice and infected with MA9-neo-expressing retrovirus. Infected
cells were selected with G418 for 2 weeks in 4-cytokine medium (10ng/ml IL-3, 25ng/ml
IL6, 100ng/ml SCF and 20ng/ml GM-SCF) to generate MA9-immortalized cells (preleukemic cells or PLC in the text) with different genetic mutations. Such PLC were
transplanted into lethally- irradiated recipient mice together support bone marrow cells to
generate leukemic mice. WT, Tnfr-/-, and Rip3-/- LCs isolated from spleens and BM of the
corresponding leukemic mice were used in our studies.
To generate NF-κB signal-inactivated MA9-LC, WT-LC or Tnfr-/-, LC generated
from the above experiments were infected with IκBαSR-GFP-expressing virus and
selected by FACS; these were used in our inhibitor treatment studies. IκBαSR is a mutant
form of IκBα with S32A/S36A substitutions. The protein product of IκBαSR is stable and
has more effective NF-κB inhibitory ability than does WT IκBα. To generate AP1repressed MA9-LC, WT-LC generated from the above experiments were infected with
DN-AP1-GFP-expressing virus. Infected LC were purified by FACS and subsequently
used in our studies.
Reagents
Rip-1 inhibitor Necrostatin (Nec1) was purchased from Santa Cruz
Biotechnology. Recombinant murine-IL-3 (rm-IL-3), rm-IL-6, rm-SCF and rm-GM-CSF
were purchased from eBioscience (San Diego). TNFα was purchased from BD
Biosciences. BAY11-7085 and SP600125 small molecule inhibitors were purchased from
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Millipore. LY294002 was purchased from LC Laboratories. JNKi I peptide and negative
control were obtained from Millipore/Calbiochem. Cell lysis buffer (10x) was obtained
from Cell Signaling, and supplemented with proteinase inhibitors and phosphatase
inhibitors (Roche Diagnostics). Anti-TNF monoclonal antibody used for blocking TNF
signaling in culture was obtained from Amgen Inc. Anti-β-Actin, GAPDH, Bcl-2, and
Bcl-xL antibodies were obtained from Santa Cruz Biotechnology. Anti-IκBα, p-IκBα,
P65, p-P65, Jnk, p-Jnk, Erk, p-Erk, p38, p-p38, Akt, p-AktS473, p-AktT308, Mcl-1,
xIAP1, Cyclin D, Il-1β primary and requisite secondary antibodies were also obtained
from Cell Signaling. c-FLIP antibody was obtained from Assay Gate. Tri-reagent used
for RNA extraction was purchased from Sigma Aldrich. TNF antibody was purchased
from Novus biologicals.
Cell culture
All cells were incubated at 37oC., 100% humidity, and 5% CO2. c-Kit+ HSPC
from indicated genotypes of mice were enriched by EasySep mouse CD117 Positive
Selection Kit (StemCell Technologies). HSPC were cultured in 6-well plates in RPMI1640 medium supplemented with 10% FBS, 1% penicillin/streptomycin, 100 ng/mL
rmSCF, 50 ng/mL rmIL-6, 20 ng/mL rmIL-3, and 20 ng/mL rmGM-CSF. All murine LC
generated in this study were cultured in such medium. Human leukemic cell lines were
cultured following instructions from ATCC.
Cell counting
Cell number was determined by trypan blue exclusion using 0.4% trypan blue
(Gibco). At each 24-hour interval, all cells were harvested from the plate, centrifuged, re	
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suspended in 1 mL of complete medium, and a sample was taken for counting. All cell
counting was performed using trypan blue exclusion as visualized in a hemocytometer
under 40× magnification. After counting, cells were re-suspended in a total of 3 mL
medium and re-plated. This was repeated every 24 hours for 4 repetitions.
Colony-Forming Unit assay
Indicated genotypes of murine LC or BM cells were seeded into MethoCult GF
M3434® (StemCell) at 1000 cells/mL (LC) or 20,000 cells/mL (BM HSPC), incubated at
37oC, 100% humidity, and 5% CO2 for 7 days (LC) or 10 days (HSPC cells). Numbers of
colonies were counted according to the manufacturer’s instructions. Clusters of cells
containing >50 cells were counted as colonies. Triplicated experiments were performed
in all of our studies. All data were verified by three individual experiments.
Human AML cell lines were seeded into MethoCult base medium without
cytokines at 1000 cells/mL and incubated and read as murine LC. Primary AML patient
samples were seeded into MethoCult 4035 Optimum without EPO and incubated at 37oC,
100% humidity, and 5% CO2. Colonies were read 14 days following seeding. Clusters of
cells containing >50 cells were counted as colonies. Triplicated experiments were
performed in all of our studies. All data were verified by three individual experiments.
Cell death assay
HSPC or LC were incubated in medium with or without inhibitors for 24 hours.
Cells were then stained with alloyphycocyanin-conjugated Annexin V in Annexin
binding buffer following the manufacturer’s instructions (BD Biosciences). Cell death
was determined by the percentages of Annexin V+ cells.
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Detection of nuclear localization of NF-κB by Amnis Imagestream-X
Cells were fixed and permeabilized using BD Fix/Perm kit as described by the
manufacturer. Intracellular staining was performed using p65 antibodies (Cell Signaling),
Alex-647 secondary (e-Biosciences) and DAPI. Nuclear localization of p65 was
determined using a similarity dilate algorithm determined by Imagestream Ideas software
and analyzed per 5000 cells. Significant differences were determined by mean and
standard deviation values provided by Imagestream Ideas and compared student’s t-test.
Retroviral infection
High titer retrovirus was produced by co-transfecting Phoenix cells with a
retroviral vector containing the indicated genes together with packaging vectors using
Calphos Mammalian Transfection Kit (Clontech). Retroviral supernatants were harvested
24 and 48 hours after transfection. Retroviral plasmids MSCV-GFP and MSCV-Cre-GFP
were kindly provided by Dr. Chao Niu of the University of Southern California, MSCVMLL-AF9-neo was kindly provided by Nancy Zeleznik-Le of Loyola University
Chicago, MSCV-IκBαaa-GFP was generated by sub-cloning the IκBαaa gene from
pBabe-IκBαaa-puro plasmids (kindly provided by Dr. Mitchel Denning, Loyola
University Chicago) into the MSCV-IRES-GFP vector. pMieg-DN-AP1 was obtained
through Addgene. Viruses were generated using these retroviral vectors. LC or c-kit+
HSPC were transduced with such virus-expressing genes of interest by spinoculation at
32oC., 2000 rpm for 4 hours. Cells were then incubated using standard culture conditions
as described above, and GFP% of representative samples were read by flow cytometry
every 24 hours. This assay allowed us to evaluate the functions of genes on cell growth
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with both internal control (GFP- non-transduced cells) and external control (MSCV-GFP
infection). Transduced cells were also purified by FACS for CFU assay.
Western Blot analysis
LC/HSPC (106) were plated in 6-well plates for 5 hours in RPMI-1640 medium
supplemented with 10% FBS. FBS was present at all times during experiments, and did
not show any effect on the measured signals. Growth factors were removed during this
phase to reset the cell signaling to an unstimulated, basal rate. After 5 hours of growth
factor withdrawal, inhibitors were added if required for 1.5 hrs. Following inhibition,
cells were stimulated if required for 10 minutes and removed from the plates then lysed
using cell lysis buffer (Cell Signaling) supplemented with protease and phosphatase
inhibitor cocktails (Roche). Contents were resolved on 10% SDS-PAGE and visualized
following transfer to nitrocellulose membranes.
Ex vivo transplantation
104 LC (CD45.2+) were plated in each well in a suspension culture and treated
with indicated doses of BAY11-7085, SP600125, anti-TNF antibody (Amgen) in
indicated combinations for 12 hours. All cells in each well were harvested and mixed
with 106 support BM cells (CD45.1+) then equally transplanted into 5 lethally-irradiated
recipient mice (CD45.1+). Mice were monitored for leukemia development by observing
for symptoms: hunched body, significant weight loss, or hind-limb paralysis. Leukemia
was confirmed by examining CD45.2+ LC in PB, spleen and BM, as well as liver and
kidney infiltration.
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In vivo transplantation and treatment
2x104 LC were transplanted into sub-lethally irradiated C57BL6/J mice with
2x105 support BM cells via tail vein injection. Twenty days after transplantation, mice
were treated with 10mg/kg InVivoMAb anti m-TNFα or IL-1 receptor antagonist
(BioXcell) and 10 mg/kg BAY11-7085 individually or in combinations every other day
for 10 days. Mice were monitored for leukemia development by lethargy, paralysis,
significant weight loss and/or enlarged abdomen. Leukemia was verified after the mice
were sacrificed by examining infiltration of LC in livers, lungs and spleens.
shRNA knockdown
LC were transduced with retrovirus-expressing shRNAs (Origene) specifically
targeted to c-Jun (TG501139), Mkps (1:TG514083; 3:TG514782; 5:TG513100), or IL-1
receptor (TG501076). The transduced cells were selected for one week using puromycin
to obtain stably transduced cells. Knockdown efficiency was examined by Western blot
(c-Jun), or RT-PCR (Mkps). Scrambled shRNAs were transduced and studied in parallel
as controls.
Primary human samples
Peripheral blood samples from AML patients were obtained from the clinic at
Loyola University Medical Center in accordance with the IRB protocol. Leukemic blasts
in PB of all patients were 30-90% when samples were collected. Samples were processed
for mono-nuclear cells (MNC) by Ficoll-paque gradient centrifugation. A portion of
MNC was used for RNA extraction and TNF expression analysis; another fraction of
MNC was plated in StemSpan serum-free medium (StemCell) supplemented with
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recombinant human SCF (100 ng/mL), Flt-3L (100 ng/mL), TPO (20 ng/mL), IL-6 (20
ng/mL), and IL-3 (20 ng/mL). Cytokines were obtained from Humanzyme. Following
overnight culture, 3×105 cells from each sample were harvested and treated with the
indicated doses of BAY11-7085, SP600125, TNF, Enbrel®, or Anakinra® and plated in
methylcellulose (StemCell) for CFU assay. Colonies were read after 14 days. In addition,
serum was collected from the same patients for examination of TNF and IL-1β levels.
Statistical analysis
Significant differences were determined by student’s t test or one-way ANOVA
with Bonferonni post-hoc test, where appropriate, unless otherwise noted. Log-rank test
was used to determine statistical significance in Kaplan-meier survival curves using in
vivo murine experiments or human AML patient data from UCSC Cancer Genome
Browser analysis. * or # indicates p<0.05, ** indicates p<0.01 when compared to
vehicle-treated control or indicated groups. Other p values are indicated.

	
  

	
  

CHAPTER 4
RESULTS
Rationale and experiment design
The goal of this project is to determine TNF/IL1-mediated, NF-κB independent
survival signals that allow LCs to escape NF-κB inhibition in vivo, and understand how
LSCs use pro-inflammatory cytokines to further their own survival by reorganizing the
niche. My studies are based on a comparative model where I treat malignant cells (LCs,
AML cell lines, primary human patient samples) in parallel with normal/healthy cells
(HSPCs, Peripheral Blood Stem Cells from healthy donors, Bone marrow aspirates from
healthy donors). Each of these cells were collected, cultured, and treated according to the
needs of the experiment and read by one of several assays: hematopoietic functional
assay (colony forming units in methylcellulose), cell death assay (Annexin V/PI stain
read by flow cytometry), and biochemical assays to determine the functions of specific
proteins (western blot analysis).
Once I determined the mechanisms of TNF/IL1-mediated, NF-κB independent
survival through the above-mentioned methods, I confirmed my findings by
transplantation of LCs in to irradiated recipient mice. The mice were treated with various
inhibitors/drugs to confirm what I found in vitro is similar in vivo (Figure 17).
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Figure 17. General experiment design
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Most experiments in this dissertation will follow the same basic experiment design:
HSPCs and LCs will be treated in parallel with some sort of stimulation/inhibition, and
effects will be measured in vitro by biochemical assay, CFU assay, or cell death assay.
All mechanistic findings will be confirmed by in vivo transplantation and treatment, and
confirmation in human AML cell lines or primary patient samples.

	
  

68	
  

	
  

Aim1: Determine if TNF-JNK acts as an NF-κB-independent survival signal in
LSCs and contributes to chemoresistance to NF-κB inhibition in vivo
Cell concentration determines NF-κB inhibitor efficacy in vitro
NF-κB, a key transcriptional regulator of inflammatory cytokine stimulated
signaling, plays a central role in the development and progression of inflammationassociated cancer. In AML, TNF and NF-κB promotes LSC function in a feed forward
manner. Basal NF-κB activity is undetectable in unstimulated normal CD34+
hematopoietic stem/progenitor cells (HSPCs), but is constitutively activated in
CD34+CD38- LSCs isolated from almost all AML patients. Inactivation of NF-κB
signaling selectively eradicates LSCs in vitro especially when combined with
chemotherapy drugs without significant influence on the survival and growth of normal
HSPCs. These studies, however, use relatively purified LSCs cultured in low density
(<3x103 cells/mL), suggesting that NF-κB signaling might be an optimal target of antiAML therapy.4,14,316,317 However, when I cultured high density AML cells in in vitro
culture (5x105 cells/mL), the therapeutic effects of NF-κB inhibitor on clonogenic
leukemic progenitors and LSCs was significantly attenuated, suggesting factors secreted
by AML cells might provide protection to LSCs. The inhibitor we used (BAY11-7085,
BAY hereafter) is a small molecule that recognizes the phosphorylation sites on NF-κB
inhibitory protein, IκBα. This was observed both in vitro in methylcellulose on leukemic
progenitors (Figure 18A), and during ex vivo transplantation assaying effects on LSCs
(Figure 18B). By analyzing the expression of genes encoding inflammatory factors in
microarray data of 90 human AML samples, I initially predicted that TNF might be one
of these secreted factors. In Aim 1, I confirmed this by demonstrating that TNF prevents
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LCs from NF-kB inhibitor treatment through stimulating JNK signaling. At the end of
Aim 1, I concluded that there are additional pro-inflammatory cytokines involved beyond
Tnf providing anti-apoptotic protection to LSCs in the presence of NF-κB inhibition. In
Aim 2, I determined IL1 is another factor which is normally expressed in TNF-expressing
AML samples, and functions in parallel to TNF. I concluded that inhibition of both
TNF/IL1-JNK and NF-kB signaling might be a better treatment for AML patients whose
cancer cells express inflammatory cytokines.
Development of experimental models: murine and human AML models
TNF stimulation in most healthy tissues induces apoptosis and necroptosis via the
Caspase 8 extrinsic apoptosis pathway and the RIP1/RIP3 necroptosis pathway.
However, tumors from AML patients appear to be producing TNF and not undergoing
cell death. In order to study this phenomenon, I used a mouse model and a collection of
human AML cell lines. I also developed murine leukemia cells (LCs) by sequential
transplantation. First I isolated c-Kit+ HSPCs from bone marrow and immortalized them
through spinoculation with MLL-AF9-expressing MSCV retrovirus (I also used Runx1Eto and CbfB-Myh11 fusion genes as TNF non-expressing and expressing LCs172). These
MLL-AF9-expressing cells are now considered pre-leukemia cells (PLCs), and are
virtually indistinguishable from their fully transformed counterparts (LCs) in vitro. These
cells were transplanted 2-5x106 cells into lethally-irradiated recipient mice and collected
the spleen and bone marrow after leukemia disease development 3-4 months following
transplantation. These collected cells are fully transformed leukemia cells (LCs), and
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Figure 18. Cell concentration determines NF-κB inhibitor efficacy in vitro

A) LCs were cultured and treated overnight at the indicated concentration with an
increasing dose of BAY. 1x103 live cells per condition were plated in methylcellulose
and read for CFUs. Results shown are mean ± SD and representative of three independent
trials. B) Indicated concentrations of LCs were cultured for 12 hours in suspension
culture and treated with vehicle or BAY, then 2x103 live LCs were transplanted into
lethally-irradiated mice.

	
  

71	
  

	
  

have the ability to generate leukemias in transplant mi development 3-5 weeks following
transplantation. We used these cells (LCs) for all studies in this dissertation (Figure
19A).
These LCs produce mature Tnf, making them ideal for studying the mechanisms
of survival in TNF-producing AMLs (M3, M4, and M5). I confirmed Tnf production by
western blot of lysed cells, using an antibody that recognizes mature, cleaved Tnf (app 17
kDa). Protein levels were normalized to actin. Murine HSPCs do not produce mature Tnf
and were used as negative controls. (Figure 19B). I further confirmed the presence of
mature Tnf in LCs by intracellular labeling analyzed by flow cytometry. LCs were either
unstimulated or treated with PMA (phorbol 12-myristate 13-acetate) to stimulate protein
production, and staining gates were set to LCs stained with an antibody isotype as a
control (Figure 19C).
Any data determined from a murine model must be confirmed in a human (or
humanized) disease model before I can derive any clinically relevant meaning. Therefore,
I also utilized several human AML cell lines with a wide range of TNF expression to
confirm anything found in the murine model in human AML cells. TNF levels were
normalized to CML blast crisis cell line K562 (Bcr-Abl+), which showed the lowest
levels of endogenous TNF production. Therefore I concluded that all of our human AML
cell lines are producing at least some level of TNF higher than HSPCs, with some
producing more than others. I found the highest levels of TNF production in the APL
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Figure 19: Development of TNF-expressing murine and human AML models

A) HSPCs were isolated from WT and Tnfr-/- mice and transduced with a leukemia
fusion-MSCV retrovirus to produce PLC. PLCs were transplanted into recipient mice to
generate LC. LC were isolated from spleens and bone marrow of leukemic mice and used
for most studies in this dissertation. B) LCs produce TNF as shown by western blot
analysis of four separate transplantations of LCs into recipient mice, and were compared
to HSPCs from two non-transplanted mice. C) Intracellular TNF was measured in LC by
intracellular staining and read by flow cytometry with and without PMA stimulation.
Gating was set by comparison to isotype control. D) Relative mRNA levels of TNF
produced in established human AML cell lines. Values shown are mean ± SD based on
three independent trials. * indicates p<0.05 as determined by students T test, compared to
K562.
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(PML-RARα) cell line, NB4. This supports observations in APL patients, and our
observations in cDNA data from AML patient databases that APL tumors produce very
large amounts of endogenous TNF (Figure 19D).
Tnf receptor deletion drives growth defects in LCs
The previous data showed addition of exogenous Tnf stimulated the growth of
LCs, and removal of TNF repressed the growth. To further study this, I serially
transplanted WT and Tnfr-/- PLCs and LCs into lethally-irradiated recipient mice and
found a distinct defect in leukemogenesis of Tnfr-/- PLCs/LCs when compared to their
WT counterparts, with time to disease doubled in both cases. This effect was seen
following transplantation of both PLCs and LCs (Figure 20A).
Further comparison of Tnfr-/- and WT LCs revealed that although Tnfr-/- LCs do
not show any replating defects, they do have a reduced total ability to form colonies
during a serial replating assay when compared to WT LCs. The total colony numbers of
Tnfr-/- LCs were compared to WT LCs for control (Figure 20B). A similar effect was not
observed in HSPCs, suggesting that Tnf stimulation does not play as important a survival
role in these cells as in LCs. Tnfr-/- HSPCs were compared to WT HSPCs as control
(Figure 20C). These data suggest that Tnf plays an important survival role, and that
elimination of Tnf-dependent signaling can significantly prolong the duration until
disease occurrence in xenografted mice. This in combination with the reduction in
colony-formation in vitro would suggest blocking Tnf could be a possible anti-leukemia
therapeutic.
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Figure 20: Tnf receptor deletion drives growth defects in LCs

A) Leukemogenic capacity of WT LCs/PLCs and Tnfr-/- LCs/PLCs as compared with in
vivo transplantation. Numbers of recipient mice are indicated. B) Serial colony forming
ability was compared between WT and Tnfr-/- LCs. WT LCs were used as control. C)
CFU/10,000 cells shown for WT and Tnfr-/- HSPCs. Colony formation of WT HSPCs was
used as controls. Values shown (B and C) are mean ± SD from three independent trials. *
indicates p<0.05 when compared to vehicle treated/WT control.
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Tnf promotes LC survival and proliferation
Stimulation of LCs with exogenous Tnf promotes colony formation and increase
in cell number, while blocking Tnf through genetic deletion of its receptors or
neutralization with a monoclonal antibody slows their growth and limits colony
formation. To understand this mechanism, I measured the proliferation rates of WT and
Tnfr-/- LCs through PI stain assay, and measured the percentage of cells in G0/G1 vs
S/G2/M via DNA content. When cells proliferate, they need to replicate the DNA.
Propidium Iodide (PI) is a stoichiometric DNA dye that binds to DNA and fluoresces.
The fluorescent signal is directly related to the amount of DNA present. I found that in
addition to the colony defect observed in Figure 20, Tnfr-/- LCs also have lower
proliferation than their WT counterparts as noted by a decrease in the percentage of cells
in S/G2/M phase as determined by Propidium Iodide staining (Figure 21A).
If Tnf drives an important survival signal, then removal of the Tnf signal should
also remove the survival signal and induce some degree of cell death. I tested this by
neutralizing soluble Tnf or genetic deletion of Tnf receptors. Either of these actions
increased cell death by a slight but significant value. Cell death was measured by
Annexin V stain and compared to vehicle treated WT LCs as control (Figure 21B).
I also found that stimulation with exogenous Tnf also drives necroptotic cell death
in a small population of LCs, because this cell death can be completely reversed by cotreatment with a Rip1k inhibitor (Necrostatin-1, Nec1), or by genetic deletion of Rip1k’s
necroptosome binding partner Rip3 (Figure 21C). WT LCs treated with vehicle were
used as controls.
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Figure 21: Tnf promotes LC survival and proliferation

A) 1x106 LC of indicated genotype were grown in suspension in 6-well plates, fixed and
permeabilized, then stained with saturating levels of PI. DNA content was measured by
flow cytometry, and gates were set with G0/G1 indicating all values ≤2n DNA, and
S/G2/M indicating all values ≥2n DNA. Results shown are indicative of three
independent trials. B) LC of indicated genotypes were treated overnight with 20 ng/mL
Tnf mAB and assayed for cell death by Annexin V stain. Tnfr-/- LC were used as
controls. C) Indicated genotypes of LCs were treated overnight with exogenous Tnf (50
ng/mL) and/or Necrostatin-1 (Nec1, 30 mM). Cell death was measured by Annexin V
stain by flow cytometry. Results shown are mean ± SD. * indicates p<0.05 when
compared to vehicle treated WT LC control as analyzed by students t test. # indicates
p<0.05 of WT LCs treated with Tnf mAB when compared to WT LCs treated with
vehicle.
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Tnf produced by LCs induces apoptotic and necroptotic cell death in HSPCs
Tnf’s normal role in most tissues studied is to induce apoptosis and necroptosis
through the extrinsic (complex 2) apoptosis pathway. I confirmed this in HSPCs by
treating HSPCs with a combination of exogenous Tnf and Nec1, and measured cell death
by Annexin V stain. HSPCs showed a significant increase in cell death when treated
overnight with Tnf that was partially rescued by Nec1 treatment, suggesting that the cell
death induced by Tnf was primarily necroptotic (can be rescued by Nec1), with some
apoptosis (cannot be rescued by Nec1) (Figure 22A). WT HSPCs treated with vehicle
and Tnfr-/- HSPCs were used as negative controls.
To measure the direct activation of Caspase-8-mediated apoptosis following Tnf
stimulation, I treated WT and Rip3-/- HSPCs in parallel with Tnf and a Caspase-8-specific
inhibitor Z-IETD-FMK. Rip3-/- HSPCs are unable to undergo necroptosis upon
stimulation, and co-treatment with Caspase-8 inhibitor in these cells was able to
completely prevent any Tnf-mediated cell death. This suggests that Tnf induces a
combination of apoptotic and necroptotic cell death in HSPCs. Without Caspase-8’s
catalytic inhibition of Rip1/Rip3-mediated necroptosis, the WT HSPCs underwent a
significant increase in cell death (Figure 22B). WT HSPCs treated with vehicle were used
as controls.
AML patients commonly show significant hematopoietic repression in later stages
of the disease. I propose that this is due to LCs secreting pro-inflammatory cytokines,
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Figure 22: Tnf produced by LCs induces apoptosis and necroptosis in HSPCs

A) WT HSPCs and Tnfr-/- HSPCs were cultured in medium with or without exogenous
Tnf. Nec1 was used to block necroptosis. B) HSPCs from WT (Rip3 WT) and Rip3-/- mice
were cultured with or without Tnf. Z-IETD-FMK was used to inhibit Caspase 8 activity.
Cell death was examined 24 h after Tnf treatment. C) Tnf secreted by LCs is sufficient to
induce cell death in HSPC. WT and Tnfr-/- HSPCs were incubated in fresh medium or 1:5
conditioned/fresh medium from LC culture and treated with or without anti-TNF mAb. *
indicates P < 0.05 when compared with vehicle treated control (A–C and G–M) or WT
control (D–F) as determined by Student’s t test analysis. # indicates P < 0.05 significant
difference when compared with indicated conditions. Values shown are mean ± SD
analysisfrom three independent trials, unless otherwise notated.
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thereby inducing cell death and depleting the healthy stem cell population. To test this, I
conditioned media with LCs, diluted 1:5 in fresh media, and grew HSPCs overnight.
Annexin V was measured the following day. I found that cytokines secreted by LCs were
sufficient to induce cell death in HSPCs. The effect was mostly removed by neutralizing
soluble Tnf, or by use in Tnfr-/- HSPCs, suggesting this effect is directly due to Tnf
(Figure 22C). Because this effect could not be completely neutralized, I proposed that
there may be additional pro-inflammatory cytokines secreted by LCs in addition to Tnf.
Such a cytokine would promote LC proliferation and induce cell death in HSPCs. I
identified that this cytokine is IL-1, and will be discussed later.
Tnf stimulates NF-κB activity in HSPCs and LCs
NF-κB is the best-studied effector of Tnf-mediated survival signaling in most
tissues studied. LSCs require NF-κB activity for survival and self-renewal. The standard
method of measuring NF-κB activity is nuclear localization of subunits and activation of
target genes. I measured nuclear localization of NF-κB subunit p65 following stimulation
with Tnf by Imagestream Analysis and found that Tnf does induce nuclear localization in
both HSPCs and LCs, suggesting Tnf can induce NF-κB activity (Figure 23A). Results
were compared to vehicle treated cells as negative controls. Phosphorylation of p65
subunits by IKKβ occurs following release and degradation of the IκBα repressor
subunits, and can also be used as a marker for NF-κB activity (Figure 23B). Untreated
HSPCs and LCs were used as controls.
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Figure 23: Tnf induces NF-κB activity in HSPCs and LCs

A) Tnf stimulation of NF-κB activity in both LC and HSPC as shown by p65 (NF-κB1)
nuclear localization (values in parenthesis are mean similarity dilate peak, sample size =
5,000 cells) as determined by ImageStreamX. Horizontal scale bars indicate 10 µm. B)
Tnf stimulation of p65 phosphorylation in HSPCs and LCs. C) HSPC and LC stimulated
with individual hematopoietic cytokines show different patterns of p65 phosphorylation.
* indicates p<0.05 when compared to vehicle treated controls as determined by Student’s
t test two-tailed analysis. All results shown are indicative of three independent trials.
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NF-κB is highly upregulated in LCs when compared to HSPCs. I observed that a
main reason for this is that HSPCs appear to only be able to activate NF-κB when
stimulated by Tnf (and slight activity when stimulated with SCF). However, LCs are able
to translate stimulation by all hematopoietic cytokines into NF-κB activity, suggesting a
mechanism for elevated NF-κB activity in these cells (Figure 23C).
LCs are more sensitive to NF-κB inhibitor in vitro than HSPCs
A 2001 study by Guzman et al. found that NF-κB is constitutively expressed in
LSCs, and that NF-κB activity is critical for maintaining LSC properties. This activity
appears confined to LSCs, as HSPCs do not express high levels of NF-κB. Therefore this
is a therapeutic window where, in vitro, one can kill LSCs before having an adverse
effect on HSPCs. These observations were made in lin-CD34+CD38- human AML cells.
Although our murine AML model (MLL-AF9 LCs) fits the human disease model by
expressing pro-inflammatory cytokines TNF and IL1, I needed to confirm that these cells
would also be sensitive to NF-κB inhibition. To accomplish this, I utilized a small
molecule BAY11-7085 (BAY hereafter). BAY is a membrane-permeable ATP analogue
that can bind to the IκBα repressor subunit of NF-κB, preventing its phosphorylation and
subsequent degradation by the proteosome.
I tested BAY inhibitor treatment in HSPCs and LCs in parallel in both
methylcellulose culture and suspension culture. I found that LCs reduced their CFUs in a
dose dependent manner in response to increasing BAY concentrations (Figure 24A).
90% of LC colonies were removed when treated with 200 nM BAY, with no effects on
HSPCs. Vehicle-treated cells from each type were used as negative controls.
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Figure 24. LCs are more sensitive than HSPCs to NF-κB inhibition in vitro

A and B) HSPCs and LCs were treated in parallel with increasing doses of BAY11-7085
(BAY) inhibitor in methylcellulose or suspension culture, respectively. A) CFUs were
read seven days following seeding. B) Cell death was measured by Annexin V staining
after overnight treatment with BAY, and read by flow cytometry. * indicates p < 0.05
when compared with vehicle treated control, ** indicates p < 0.01 as determined by
Student’s t test analysis. Values shown are mean ± SD analysis from three independent
trials.
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I confirmed that the drop in colony number was due to an increase in cell death by
treating HSPCs and LCs in parallel in suspension culture overnight with increasing doses
of BAY inhibitor. There was an eight-fold increase in cell death in LCs without any
significant change in HSPCs (Figure 24B).
Tnf receptor deletion protects HSPCs from NF-κB inhibitor effects
In most tissues studied, NF-κB promotes a strong survival signal that can
counteract cell death caused by pro-inflammatory cytokine stimulation by upregulation of
anti-apoptotic genes. HSPCs behave in a similar fashion. I tested this by treating WT and
Tnfr-/- HSPCs in parallel with a gradient of BAY NF-κB inhibitor. If HSPCs underwent
TNF-mediated cell death in the presence of the inhibitor, then there would be a drop in
colonies and an increase in Annexin V staining that could be reversed by inhibition of the
Tnf signal. In this case, I deleted both Tnf receptor genes (Tnfr1-/-Tnfr2-/-, Tnfr-/- for
simplicity). As expected, I found that Tnfr-/- HSPCs are more resistant to CFU reduction
driven by high-dose treatment with BAY (Figure 25A).
In order to confirm the specific of the BAY inhibitor, I spinoculated HSPCs (and
LCs in the future) with an MSCV retrovirus constitutively over-expressing a superrepressor mutant of the NF-κB repressor subunit IκBα, IκBαSR. IκBαSR binds all the
free NF-κB subunits in the cytoplasm, but cannot be degraded due to mutation of the IKK
phosphorylation sites (Serine to Alanine). This construct is able to completely block NFκB activity and has been used experimentally in cells from several tissues including skin,
liver, and intestine. I found HSPCs expressing IκBαSR showed a reduction in CFU that
was rescued by Tnf receptor deletion (Figure 25B). This confirmed that the activity
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Figure 25. Tnf receptor deletion protects HSPCs from NF-κB inhibitor effects

WT and Tnfr-/- HSPCs were treated in parallel with increasing doses of BAY (A), or
expressing IκBαSR (B) in methylcellulose culture. Results shown are mean ± SD. *
indicates p<0.05, ** indicates p<0.01 when compared to vehicle treated cells by
Student’s t test. # indicates p<0.05 when compared to indicated conditions by Student’s t
test.
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of the BAY inhibitor was due to specific inhibition of NF-κB. Vehicle-treated/vectorexpressing cells were used as the negative control.
Tnf receptor deletion sensitizes LCs to NF-κB inhibitor effects
I attempted to confirm our results from BAY and IκBαSR experiments in HSPCs
by performing similar experiments in LCs. However, I found that while Tnf receptor
deletion protected HSPCs from NF-κB inhibition, the opposite was the case with LCs. By
blocking the Tnf signal, I actually sensitized LCs to NF-κB inhibition by treatment with
BAY (Figure 26A). Vehicle treated cells were used as negative controls.
I confirmed the specificity of BAY in LCs by overexpressing IκBαSR on a
retrovirus and measuring similar results. I found that, like BAY, IκBαSR also affected the
Tnfr-/- LCs more than the WT LCs. It should be noted that WT LCs have a greater
reduction in CFUs when overexpressing the IκBαSR than WT HSPCs. Overexpression of
IκBαSR reduced CFU by 90% in Tnfr-/- LC (Figure 26B).
These results suggest that Tnf may be an NF-κB-independent death signal in
HSPCs and an NF-κB-independent survival signal in LCs. If Tnf drives an NF-κBindependent survival signal, then treatment with additional exogenous Tnf should rescue
some of the CFU reduction due to NF-κB inhibition. I found this to be the case, with a
slight but significant rescue of colonies in WT LCs (Figure 26C).
This led us to question what this signal could be. The previous two experiments
suggest that there is a common signal between the two cell types that is independent of
NF-κB, stimulated by Tnf, and acting differently between the two cell types. Such a
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Figure 26. Tnf receptor deletion sensitizes LCs to NF-κB inhibitor effects

A) WT LCs and Tnfr-/- LCs were treated in parallel with increasing doses of BAY in
methylcellulose for CFU assay. Vehicle treated cells were used as negative control. B)
WT LCs and Tnfr-/- LCs were spinoculated with IκBαSR-expressing retrovirus and plated
in methylcellulose. Cells transduced with empty vector are used as negative controls. C)
WT LCs were treated with indicated doses of BAY, or exogenous Tnf and plated in
methylcellulose. Values shown are mean ± SD from three independent trials. * indicates
p<0.05, ** indicates p<0.01 when compared to vehicle/vector control as determined by
Student’s t test. # indicates p<0.05, ## indicates p<0.01 when compared to indicated
condition as determined by Student’s t test.
Figure 26 Model:

Common signal between HSPCs and LCs drives cell death in HSPCs and cell
survival/proliferation in LCs. 	
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signal would be a survival mediator in LCs and a death mediator in LCs
(Figure 26 Model).
JNK is stimulated by Tnf in LCs
I next determined which Tnf-mediated signal is responsible for driving NF-κBindependent cell survival/proliferation in LCs, and cell death in HSPCs. To do this, I
treated HSPCs and LCs in suspension culture with each of the various hematopoietic
cytokines used in culture: IL3, IL6, Granulocyte/Macrophage-Colony Stimulating Factor
(G-CSF), Stem Cell Factor (SCF), and Tnf. Following 15 minutes of stimulation, cells
were lysed and contents analyzed by western blot analysis for activation of several
known survival signals in hematopoietic cells, involved in the SAPK, MAPK, and AKT
pathways. I tested the activity of p-Jnk, p-Erk, p-p38, p-AktS473, and p-AktT308. Vehicle
treated cells were used as negative controls, and total protein levels were normalized to
GAPDH, a metabolic protein.
I found Tnf stimulation activated Jnk, Erk, p38, and AktS473 (PI3k activation
pathway) in both HSPCs and LCs. It should be noted that while Erk, p38, and Akt can be
stimulated by multiple cytokines, only Jnk appears to be Tnf-mediated. IL3 and SCF
appear to be able to repress Jnk phosphorylation, but this mechanism was not pursued
further. IL6 and G-CSF are known activators of Jnk in many tissues, and also activated
Jnk in our experiments. p38, a Mapk, was also activated in a similar pattern to Jnk in both
HSPCs and LCs. However, p38 was more strongly activated by GM-CSF and SCF than
Jnk. p38’s role in Tnf-mediated leukemogenesis will be measured later. Erk and Akt were
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Figure 27: Jnk is primarily stimulated by Tnf in HSPCs and LCs

HSPCs and LCs were treated in suspension for 15 minutes with indicated hematopoietic
cytokines. Cells were lysed and contents resolved by SDS-PAGE and assayed by western
blot analysis. Protein levels were normalized to β-Actin for loading control. Vehicle
treated HSPCs and LCs were used as negative control.
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both activated by multiple cytokines, and were not particularly strongly activated by Tnf
stimulation. Erk and Akt were activated by IL3 and GM-CSF (Figure 27).
Jnk is activated by Tnf, independently of NF-κB, promotes LC colony formation
Our previous studies showed that there is a Tnf-mediated and NF-κB independent
signal that is a survival mediator in LCs but a cell death mediator in HSPCs. When
studying the effects of different hematopoietic cytokine stimulation, I determined Jnk and
p-38 were primarily activated by Tnf, making these two proteins possible contenders. To
test which of these survival signals fit the criteria, I treated HSPCs and LCs in parallel in
suspension culture first with BAY for two hours, and then added Tnf for 15 minutes. Any
NF-κB-independent/Tnf-dependent signals would be activated upon Tnf stimulation and
remain activated or increase in activation in the presence of BAY.
I found Erk and AKt were repressed by BAY in LCs, suggesting these signals
require NF-κB for activity. These were different in HSPCs and LCs, with BAY treatment
enhancing their respective activities, suggesting a possible compensantory mechanism in
HSPCs. Jnk and p-38 were active in the presence of Tnf and BAY (Figure 28A).
To determine which of these mediate survival signals, I treated HSPCs and LCs in
parallel with small molecule inhibitors specific for each protein: (SB253580, p38;
SP600125, Jnk; PD98059, Erk). Erk inhibitor had no observed effect on LC CFUs. p38
inhibition actually increased the CFUs of LCs while decreasing CFUs in HSPCs,
suggesting p38 represses cell death in LCs and promotes cell death in HSPCs, which
would make it a poor choice for anti-leukemia therapies. Jnk inhibition increased HSPC
CFUs and decreased LC CFUs, making this a survival signal in LCs and a death signal in
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Figure 28. Jnk is a Tnf-dependent, NF-κB-independent survival signal

A) HSPCs and LCs were pre-treated with BAY for two hours, followed by stimulation
with Tnf for 15 minutes. Cells were lysed, contents resolved by SDS-PAGE, and
analyzed by western blot. Protein levels were normalized to GAPDH for loading control.
Vehicle treated cells were used as negative controls. B) HSPCs and LCs were treated in
parallel with p38 inhibitor (SB253580), Jnk inhibitor (SP600125), and Erk inhibitor
(PD98059). Total number of colonies is shown. Values shown are mean ± SD. * indicates
p<0.05 when compared to vehicle treated control by Student’s t test.
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HSPCs, suggesting Jnk is the Tnf-mediated, NF-κB survival signal in LCs, and death
signal in HSPCs (Figure 28B).
Jnk inhibition drives cell death in LCs
The previous study suggested Jnk functioned as a survival signal in LCs. To test
this, I used two different Jnk inhibitors: a small molecule inhibitor (SP600125, SP6
hereafter), and a Jnk binding domain peptide (aa sequence:
GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT) that interferes with upstream
SAPKK activation of Jnk. Both of these inhibitors were able to completely block Tnfmediated Jnk phosphorylation and subsequent c-Jun phosphorylation (Figure 29A). Cells
treated with a control peptide (aa sequence: GRKKRRQRRRPP) were used as negative
control.
Treatment with SP6 in HSPCs and LCs showed that Jnk inhibition promotes cell
death in LCs at a much lower concentration than in HSPCs in a dose dependent manner
(Figure 29B). I noted that at high concentrations, SP6 can cause cell death in HSPCs.
However, SP6 has complete Jnk inhibition at 10 µM. Any effects observed at
concentrations above 10 µM could be attributed to non-specific toxicities. Cells treated
with vehicle were used as negative controls.
I confirmed the effects of SP6 in HSPCs and LCs by treating both cell types in
parallel with another Jnk inhibitor, which was a peptide mimetic of Jnk-binding domain,
JNKi-I(L). This peptide also showed a dose-dependent effect on LCs, suggesting a
specific activity is due to blocking Jnk. At high concentrations (10 µM), I observed a
large decrease in CFUs of LCs without any decrease in HSPC CFUs (Figure 26C). Cells
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Figure 29: Jnk inhibition promotes cell death in LCs

A) LCs were treated in suspension culture with indicated JNKi-I(L) or SP6 for 2 hours
before stimulation with Tnf for 15 minutes. Cells were lysed and contents resolved by
SDS-PAGE and Jnk/c-Jun activity was determined by western blot. Negative control
(n.c.) peptide was used as negative control. B) HSPCs and LCs were treated in parallel
with increasing doses of SP6 inhibitor in methylcellulose. Vehicle treated cells were used
as negative controls. C) HSPCs and LCs were treated in parallel with increasing doses of
JNKi-I(L) peptide in methylcellulose. Negative control-peptide treated cells were used as
negative control. D) HSPCs and LCs were treated in suspension culture with increasing
doses of SP6 overnight. Cell death was measured the following day by Annexin V
staining and read by flow cytometry. Vehicle treated cells were used as negative control.
A is representative of three independent trials. Values shown are mean ± SD. * indicates
p<0.05, ** indicates p<0.01 by Student’s t test.
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treated with a control peptide that has key JNK binding domain interaction amino acids
mutated were used as negative controls.
Finally, I attributed the reduction in CFUs to an induction of cell death by treating
HSPCs and LCs in parallel in suspension culture with increasing doses of SP6.At 10 µM,
70% of LCs were Annexin V positive, while no significant increase in HSPC cell death
was observed (Figure 29D). Vehicle treated cells were used as controls.
Jnk is a Tnf-mediated survival signal in LCs, death signal in HSPCs
I identified that Jnk functions as a survival signal in LCs by treating LCs with a
Jnk inhibitor and reducing the colony formation. Next, I needed to determine if Jnk was
acting as a Tnf-mediated (to be specific) survival signal in LCs, and a Tnf-mediated death
signal in HSPCs. To accomplish this I treated HSPCs and LCs in parallel with SP6 or
exogenous Tnf individually or in combination. If Jnk acted as a Tnf-mediated survival
signal, then CFUs gained by Tnf stimulation could be prevented by treatment with SP6.
On the other hand, if Jnk acted as a Tnf-mediated death signal, then loss of CFUs due to
Tnf stimulation could be rescued by co-treatment with SP6. I found that Tnf treatment of
HSPCs, in agreement with our earlier data, caused a 50% drop in CFUs that was partially
rescued by co-treatment with SP6, suggesting that Jnk functions as a Tnf-mediated death
signal. However, in LCs, co-treatment of SP6 and Tnf reduced CFUs by as much as 50%,
suggesting Jnk functions as a Tnf-mediated survival signal (Figure 30A). Vehicle treated
cells were used as control.
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Figure 30: Jnk is a Tnf-mediated survival signal in LCs, death signal in HSPCs

A)	
  HSPCs and LCs were treated in parallel with SP6 and Tnf individually or in
combination in methylcellulose culture and plated for CFU assay. Numbers of CFUs
were normalized to vehicle-treated HSPCs and LCs, respectively. B) HSPCs were treated
overnight with Tnf or SP6 individually or in combination in suspension culture. The
following day, cell death was measured by Annexin V assay and read by flow cytometry.
Vehicle treated cells were used as negative controls. Values shown are mean ± SD from
three independent trials. * indicates p<0.05 when compared to vehicle control as
measured by Student’s t test. # indicates p<0.05 when compared to indicated groups as
measured by Student’s t test.
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The reduction in HSPC CFUs following Tnf stimulation appeared to be almost entirely
due to induction of cell death, and more specifically Jnk-mediated cell death. This is
because co-treatment of Tnf and SP6 in HSPCs almost completely prevented all
Tnf-mediated cell death in these cells (Figure 30B). Vehicle treated HSPCs were used as
control.
Tnf-mediated Jnk activation is attenuated in LCs
Jnk activation can play opposing roles in tissues depending on the nature of its
activity. For example, the pro-survival function of Jnk is related both to its duration of
activity (< 2 hrs) as well as its nuclear substrates in the Jun/Fos AP-1 family of
transcription factors. This results in activation of survival and proliferative genes through
the AP1 transcription factors binding to appropriate target genes. In opposition, the proapoptosis function of Jnk is, in turn, related to its duration of activity (> 2 hrs) as well as
its cytoplasmic substrates. When phosphorylated by Jnk, pro-apoptotic Bim, Bad, Bax,
Bak, and Bid increase in affinity for the puncturing the mitochondrial membrane and also
prevent Bcl-2 family antiapoptotic genes from protecting the mitochondria. This results
in release of cytochrome C leading to activation of executor caspases and apoptosis.
I hypothesized that because Tnf-stimulated Jnk is acting as a survival signal in
LCs and death signal in HSPCs, that there would be stringent regulation of Jnk
phosphorylation in LCs (<2 hrs). To test this I treated cytokine-starved HSPCs and LCs
in suspension culture with exogenous Tnf for a time course experiment extending from
15 minutes to 240 minutes (4 hours). I found that both HSPCs and LCs have the most
activity of Jnk 15 minutes after stimulation. But when LCs are able to return to a basal,
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Figure 31: Tnf-mediated Jnk activity is attenuated in LCs

A) HSPCs and LCs were stimulated with exogenous Tnf for indicated time (in minutes).
Jnk activity was determined by western blot analysis for phosphorylated Jnk. Protein
levels were normalized to GAPDH for loading control. Vehicle treated cells were used as
control. B) Pixel analysis was performed using p-Jnk blots and normalizing the arbitrary
units to GAPDH for each. Fold change in p-Jnk levels were compared to vehicle (0 min)
treated cells. Results shown are representative of three independent trials.
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unstimulated level of Jnk phosphorylation after 60 minutes, HSPCs have Jnk activity that
persists up to 4 hours following stimulation (Figure 31A). Total signal was analyzed
using pixel analysis and normalized to GAPDH strength as internal loading controls
(Figure 31B). Vehicle treated cells were used as negative control.
LCs attenuate Jnk signal strength through Tnf receptor endocytosis
There are two possible mechanisms for attenuating the Jnk signal duration: LCs
can either endocytose the Tnf receptor thereby removing the stimulus, or LCs can directly
dephosphorylate Jnk with a Map Kinase Phosphatase (Mkp). I tested the first possibility
by treating HSPCs and LCs with Tnf for a timecourse and measured surface expression
of Tnf receptor. If Tnf stimulation drove endocytosis of the receptor, then the mean
fluorescence intensity should decrease, and the curve should shift to the left (this
antibody recognizes a different sequence on the extracellular portion of the receptor than
binds the ligand, so I can be confident that ligand binding does not displace the antibody,
or vice versa). I found that LCs do endocytose the receptor in response to ligand binding
when compared to HSPCs (Figure 32A). HSPCs and LCs lacking the Tnf receptor were
used as negative control.
Tnf receptors are endocytosed via the classic clathrin-mediated pit mechanism.
The final step of clathrin-dependent endocytosis is the cinching and sealing of the
internalized vesicle by an ATP-dependent protein called dynamin, which can be inhibited
by a small molecule called Dynasore. I expected to be able to prolong the Jnk signal in
LCs by blocking endocytosis, but I found that the signal was only slightly prolonged (still
active at 60 minutes). However, I did note that the signal of phosphorylated Jnk was
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Figure 32: LCs attenuate Jnk signal strength through Tnf receptor endocytosis

A) HSPCs and LCs were treated with exogenous Tnf (20 ng/mL) for indicated times,
then stained for Tnfr1a expression and read by flow cytometry. Tnfr-/- HSPCs and LCs
were used as negative controls. Results shown are indicative of three independent trials.
B) HSPCs and LCs were treated with exogenous Tnf (for indicated time in minutes) and
Dynasore individually or in combination. Phosphorylated Jnk was measured by western
blot analysis. Results shown are indicative of three independent trials. C) LCs were
treated with Dynasore or Tnf alone or in combination overnight in suspension culture.
Cell death was measured the following day by Annexin V staining and read by flow
cytometry. Results shown are mean ± SD. * indicates p<0.05 when compared to vehicle
control as determined by Student’s t test. # indicates p<0.05 between indicated groups.
Other p values are noted.
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significantly strengthened (Figure 32B). I then found blocking endocytosis did enhance
overall cell death in LCs, but addition of exogenous Tnf did not further enhance cell
death (Figure 32C). I concluded from these results that LCs are utilizing receptor
endocytosis to regulate the Jnk signal, but only by controlling the signal strength.
Mkps are stably expressed in LCs in response to Tnf
The previous figure showed how LCs can endocytose the Tnf receptor in order to
limit the signal strength of Jnk. This mechanism did not have a major effect on the Jnk
signal duration though, and LCs were still able to return Jnk phosphorylation to an
unstimulated level after one hour. Therefore, there must be additional mechanisms in
place to limit Jnk activity. These are the Map Kinase Phosphatases (Mkp). Mkps are
poorly understood dual-specificity proteins that can dephosphorylate and inactivate the
map kinases. Mkps 1, 3, 5, and 7 were shown to have some interactions with Jnk,
therefore I hypothesized that one of these Mkps were responsible for regulating Jnk in
LCs. Mkps are regulated at the level of transcription, so I first assayed for total transcripts
of each Mkp (1, 3, 5, and 7). Results displayed are normalized to each condition in
HSPCs. I found that only Mkp1 is upregulated in LCs (Figure 33A).
Mkp transcription changed in response to Tnf stimulation. I hypothesized that Tnf
would stimulate necessary regulation mechanisms for Tnf targets, and I found that Tnf
stimulation did increase Mkp1 and 7 transcription in both HSPCs and LCs. Tnf drove a
repression of Mkp3 and 5 transcription in HSPCs (Figure 33B). Even though Tnf drove
changes in Mkp7 transcription levels, Mkp7 was not significantly changed between
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Figure 33: Mkps are stably expressed in LCs during Tnf stimulation

A) HSPCs and LCs were analyzed by qRT-PCR to determine relative transcription of
Mkps. Results shown are normalized to levels in HSPCs for each type of Mkp. Results
shown are mean ± SD from three independent trials. * indicates p<0.05 when compared
to HSPC transcription level, as determined by Student’s t test. B) HSPCs and LCs were
treated with Tnf for indicated times, and Mkp transcription at each time was assayed by
qRT-PCR. Values shown are mean ± SD from three independent trials, and are
normalized to vehicle treated cells as control. * indicates p<0.05 when compared to
vehicle treated cells, # indicates p<0.05 when compared to indicated groups, both
determined by Student’s t test (n.s. = non significant).
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HSPCs and LCs, and was not further studied. HSPCs displayed a significant drop in
Mkp3 and 5 levels during the course of Tnf treatment, suggesting that Tnf can repress
expression of these genes. However, Mkp3 and 5 levels were not changed in LCs during
the course of Tnf stimulation.
Mkp5 regulates Jnk activity in LCs
I determined that several Mkps are either upregulated or maintained differentially
in LCs than in HSPCs in response to Tnf stimulation (Mkp1/3/5). In order to determine
which of these is responsible for Jnk regulation in response to Tnf in LCs, I knocked
down Mkp1, 3, and 5 in LCs using shRNA constructs, and measured knockdown by
qRT-PCR (Figure 34A). Scrambled shRNA was used as negative control, and the best
knockdown was used for future experiments.
I were expecting that knockdown of Mkp1 would prolong p-Jnk because it is
upregulated in LCs compared to HSPCs, and it also increases during Tnf stimulation.
However, I found that Mkp1 knockdown only slightly prolonged Jnk activation duration.
Mkp5 knockdown, however, completely eliminated LCs ability to regulated p-Jnk. In
these cells, Tnf stimulation perpetually activated Jnk (Figure 34B). Quantification of the
p-Jnk signal was performed by pixel analysis and normalized to GAPDH loading control.
Arbitrary units shown are relative to p-Jnk signal from vehicle-treated cells (Figure
34C).
Next I asked if prolonging Jnk activity in LCs would convert Jnk from a Tnfmediated survival signal to a death signal. I tested the knockdowns of Mkp1, 3, and 5 and
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Figure 34: Mkp5 regulates Tnf-mediated Jnk activity in LCs

A) shRNA knockdown of indicated Mkps in LCs. Values are normalized to scrambled
shRNA transduced control. B) LCs expressing each Mkp knockdown shRNA construct
were treated with Tnf for indicated time periods, lysed, and contents resolved by SDSPAGE and analyzed by western blot. Results shown are representative of three
independent trials. C) Quantification of western blot results in B by pixel analysis.
Arbitrary units are set for each shRNA by vehicle treated cells and normalized to
GAPDH. D) LCs expressing indicated shRNAs were treated with Tnf in methylcellulose
for colony forming unit assay. Total number of colonies is shown. Values shown are
mean ± SD from three independent trials. * indicates p<0.05 when compared to vehicle
treated cells, unless otherwise noted, by Student’s t test.
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found that Mkp5 knockdown was able to both prolong the Jnk signal in the presence of
Tnf as well as cause reduction in CFUs. Mkp1 also slightly prolonged the Jnk signal, but
apparently not enough to convert it to a death signal. These cells increased CFUs upon
Tnf stimulation (Figure 34D).
Jnk promotes Tnf-mediated LC survival by promoting Mcl-1 and c-Flip expression
I determined that Jnk is acting as an NF-κB independent, Tnf-dependent survival
signal regulated by Mkp5 in LCs. As a SAPK protein, Jnk drives target gene expression
indirectly through phosphorylation of nuclear substrate transcription factors in the AP1
(Jun/Fos) family. In order to determine which survival genes were Jnk mediated, Tnfdependent, and NF-κB independent, I grew WT and Tnfr-/- LCs in culture media without
cytokine stimulation for four hours to reset the internal protein machinery of the cell to a
basal rate. Then I pre-treated cells with either BAY or SP6 to block NF-κB or Jnk,
respectively, then added back all four hematopoietic cytokines (IL3, IL6, GM-CSF, SCF)
plus Tnf. I called this condition “5 growth factors” (5GF). Any signals that were Tnfmediated would be downregulated in Tnfr-/- LCs grown with 5GF, and any signals that
were Jnk mediated would remain downregulated in the presence of SP6 once 5GF were
added back.
I found that Tnf-mediated survival genes were from the Jun family (c-Jun, JunB,
positive controls), Mcl-1, c-Flip, and Cyclin D1. Bcl-2 and Bcl-xL were upregulated in
Tnfr-/- LCs, suggesting a compensatory mechanism for maintaining cell survival without
Tnf. Cyclin D1 levels returned following SP6 and BAY treatment, suggesting that it is a
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Figure 35: Jnk promotes Tnf-mediated LC survival by reinforcing Mcl-1 and c-Flip
expression

WT and Tnfr-/- LCs were grown in cytokine-free medium for four hours to reset the
internal protein machinery of the cell to a basal rate. Then I pre-treated cells with either
BAY or SP6 to block NF-κB or Jnk, respectively, then added back all four hematopoietic
cytokines (IL3, IL6, GM-CSF, SCF) plus Tnf. Results shown are representative of three
independent trials. * indicates specific binding of Bcl-2/Bcl-xL antibody, other bands are
non-specific.
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Tnf-mediated, NF-κB and JNK-independent cell cycle genes. Mcl-1 and c-Flip levels
returned to normal in the presence of BAY with the addition of 5GF
media condition, but were repressed with SP6 treatment, suggesting these are Jnkmediated survival genes. xIAP1 was also repressed following Jnk treatment but was not
downregulated in Tnfr-/- LCs, suggesting this protein is Jnk-mediated but Tnfindependent (Figure 35). LCs grown in 5GF culture medium were used as controls.
Jnk mediates its pro-survival signal through c-Jun
Jnk’s primary nuclear substrate for driving survival and proliferation signaling is
c-Jun. I compared c-Jun expression between HSPCs and LCs and found LCs express a
much higher level of c-Jun protein than HSPCs. Also, Tnf drives Jnk-mediated c-Jun
phosphorylation in an NF-κB-independent manner because treatment with BAY did not
repress either Tnf-mediated Jnk phosphorylation or c-Jun phosphorylation (Figure 36A).
Vehicle treated cells were used as controls.
In order to determine c-Jun’s function in driving Tnf-mediated LC survival, I
performed a shRNA knockdown experiment. LCs were spinoculated with c-Jun shRNA
expressing retrovirus, selected, and contents resolved by SDS-PAGE and western blot
analysis. I found that c-Jun shRNA1 provided us with the best knockdown. Non-specific
binding was used as loading control (Figure 36B).
If c-Jun functioned as a Tnf-mediated survival signal, then removing it via
shRNA knockdown should also eliminate Jnk’s nuclear target and convert it to a death
signal. I found this to be the case as c-Jun knockdown cells had a significant reduction in
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Figure 36. Jnk mediates its pro-survival signal through c-Jun

A) HSPCs and LCs were treated in parallel with exogenous Tnf and BAY individually or
in combination. Cells were lysed and contents resolved by SDS-PAGE and analyzed by
western blot. Vehicle treated cells were used as negative controls. Results shown are
representative of three independent trials. B) LCs were spinoculated with c-Jun shRNAexpressing constructs and selected by puromycin for one week. Knockdown efficiency
was measured by western blot. Scrambled shRNA-expressing retrovirus was used as
negative control. Results shown are indicative of three independent trials. C) shSCR and
c-Jun shRNA1 expressing LCs were treated with exogenous Tnf in methylcellulose and
CFUs measured. Results shown are mean ± SD from three independent trials. D) shSCR
and c-Jun shRNA1 expressing LCs were treated with exogenous Tnf in suspension
culture overnight and measured for cell death by Annexin V stain and read by flow
cytometry. Results shown are mean ± SD from three independent trials. * indicates
p<0.05 when compared to vehicle treated cells as measured by Student’s t test. #
indicates p<0.05 when compared to indicated groups as measured by Student’s t test.
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CFUs when treated with exogenous Tnf in methylcellulose (Figure 36C), as well as a
significant induction of apoptosis as measured by Annexin V stain following overnight
stimulation with exogenous Tnf (Figure 36D). In both cases, LCs expressing a scrambled
shRNA and treated with vehicle were used as negative controls. The amount of cell death
induced was slight but significant, though I noted that it did not seem large enough to
explain the significant drop in CFUs following Tnf stimulation. I propose that this is due
to additional members of the Jun family compensating for loss of c-Jun. To account for
this, I turned to a dominant negative form of c-Jun (TAM67).
Dominant negative AP-1 abrogated Tnf-mediated survival in LCs
I spinoculated LCs with a dominant negative AP-1 (TAM67), which contains the
necessary structures to interact with and be phosphorylated by SAPKs (Jnk1/2), then bind
other AP-1 family members. TAM67 (DN-AP1, hereafter) lacks a DNA-binding domain,
preventing the transcription factors from binding to target genes. This molecule can block
the activity of all Jun family members (c-Jun, JunB, and JunD). Overexpression of this
molecule resulted in significant defects in overall cell growth compared to nontransduced cells as determined by change in GFP% over time (Figure 37A). Addition of
Tnf enhanced this effect. It should be noted that DN-AP1 had an effect in Tnfr-/- cells,
which do not express high levels of c-Jun or JunB. I expect that this is due to JunD
compensating, but did not perform any experiments to this end. Non-transduced cells
were used as internal control.
The slight reduction in CFUs and increase in Annexin V observed by treating cJun knockdown LCs with Tnf was significantly enhanced by blocking the entire
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Figure 37. Dominant negative AP-1 abrogated Tnf-mediated survival in LCs

A) WT and Tnfr-/- LCs were spinoculated with DN-AP1 expressing GFP retrovirus in
suspension culture and were observed daily by flow cytometry for reduction in % of
GFP-expressing cells. Tnf was also added to the culture media in test groups. Vehicle
treated cells were used as negative control, non-transduced cells were used as internal
control. Results shown are representative of three independent trials. B) WT and Tnfr-/LCs were spinoculated with DN-AP1 expressing retrovirus and treated with exogenous
Tnf in methylcellulose for CFU assay. Results shown are normalized to vehicle treated
cells expressing empty vector. C) LCs were spinoculated with DN-AP1 expressing
retrovirus and treated with Tnf in suspension culture overnight. The following day, cell
death was measured by Annexin V staining as read by flow cytometry. Vehicle treated
cells expressing empty vector were used as negative control. * indicates p<0.05 compared
to vehicle treated cells by Student’s t test. # indicates p<0.05 compared to indicated test
group as determined by Student’s t test.

Figure 37 model. LC conversion of Tnf-mediated Jnk signaling to a survival signal
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transcription factor family with DN-AP1. I found that overexpression of DN-AP1
combined with exogenous Tnf treatment reduced CFUs in LCs by 80% (Figure 37B,
compared to 40-50% with c-Jun only knockdown), and increased Annexin V staining by
20% (Figure 37C, compared to 11% with c-Jun only knockdown). These suggest that
there are additional AP1 family transcription factors activated in addition to c-Jun that
need to be accounted for when trying to block Tnf-mediated survival signaling in LCs
and LSCs.
Co-inhibition of NF-κB and Jnk is protective in HSPCs, synergistic in LCs
I identified Jnk as a critical Tnf-driven pro-survival signal in LCs, but a pro-death
signal in HSPCs. This presents an interesting option for an anti-cancer therapeutic target:
blocking Jnk would induce cell death in LCs while protecting HSPCs against cell death,
and I may be able to further sensitize LCs to NF-κB inhibitor effects in vivo by blocking
the compensatory pathway. I started by measuring the effects of co-inhibition of NF-κB
and Jnk in vitro by combination treatment in methylcellulose and measuring change in
CFUs. I found co-treatment of HSPCs with BAY and SP6 at therapeutic doses had no
effect on the cells. In fact, the toxicity of over-dosing HSPCs with BAY was partially
rescued by co-treatment with SP6 (Figure 38A). Vehicle treated HSPCs were used as
negative control.
I then tested the combination therapy in WT and Tnfr-/- LCs. I found that treatment
with an even lower dose of BAY (100 nM vs 200 nM) than originally determined was
sufficient to induce >90% reduction in CFUs, as long as co-treated with SP6 (Figure
38B). As expected, both genotypes of LCs were equally sensitive to SP6 treatment, and
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Figure 38. Co-inhibition of NF-κB and Jnk is protective in HSPCs, synergistic in
LCs

A) HSPCs were treated with indicated concentrations of BAY and SP6 alone or in
combination in methylcellulose. Vehicle treated HSPCs were used as negative controls.
B) LCs were treated with indicated concentrations of BAY and SP6 alone or in
combination in methylcellulose. Vehicle treated LCs were used as negative controls.
Values shown are mean ± SD from three independent experiments. * indicates p<0.05
when compared to vehicle treated controls as determined by Student’s t test. # indicates
p<0.05 when compared to indicated groups by Student’s t test.
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the Tnfr-/- LCs were more sensitive to the low-dose BAY treatment. By inhibiting Jnk
using SP6, I were able to reduce colonies by >90% in both cell types.
Interestingly, combination treatment of Tnfr-/- LCs also reduced CFUs further than
BAY inhibitor alone, suggesting that there may be additional Jnk-mediated, Tnfindependent survival signaling. This could be due to x-IAP, as determined in Figure 35.
Vehicle treated LCs from each genotype were used as negative controls in this
experiment.
Co-inhibition of NF-κB and Jnk is most effective in Tnf-expressing LCs
Our murine model of AML that I have been using up to this point is based on
expression of the MLL-AF9 fusion gene, which only accounts for a small percentage of
diagnosed AMLs. I also generated LCs from other leukemia fusions: AML-ETO (M2
subtype) and CBFβ-MYH11 (M4 subtype) LCs. Just as observed in human AMLs, the
AML-ETO LCs did not express mature Tnf, while the CBFβ-MYH11 LCs did.
Additionally, treatment with exogenous Tnf drove an increase in CFUs in the Tnfexpressing LCs, but reduced the CFUs in the non-Tnf-expressing LCs (Figure 39A).
Vehicle treated cells were used as negative control. I confirmed Tnf and Tnf receptor
expression in both types of leukemia cells by western blot analysis.
I then tested the two additional murine leukemia cell types with the combination
treatment, BAY and SP6. The combined inhibition of NF-κB and Jnk only had a minimal
effect on AML-ETO LCs (non-Tnf-expressing LCs), while the combined inhibition had a
major effect on CBFβ-MYH11 LCs (Figure 39B). These data suggest that although the
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Figure 39. Co-inhibition of NF-κB and Jnk is most effective in Tnf-expressing LCs

A) AML-ETO and CBFβ-MYH11 LCs were treated with Tnf in methylcellulose for CFU
assay. Tnf and receptor expression was measured by western blot analysis of lysed cells.
B) AML-ETO and CBFβ-MYH11 LCs were treated with BAY or SP6 alone or in
combination at indicated doses in methylcellulose for CFU assay. Results are normalized
to vehicle treated cells. All results shown are mean ± SD. * indicates p<0.05, ** indicates
p<0.01 when compared to vehicle treated cells as determined by Student’s t test. #
indicates p<0.05 when compared to indicated experiment groups as determined by
Student’s t test.
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inhibition of NF-κB and Jnk can have an effect on most AMLs, it is most effective in
AMLs that express Tnf. Vehicle treated cells were used as controls.
Confirmation of inhibitor specificity in LCs
A major concern when working with small molecule inhibitors in live cells is the
possibility of non-specific or off-target effects of the drug. This can be tested for by cotreatment with a genetic inhibition of the same target. For example, the specificity of the
BAY inhibitor can be measured by co-treatment with DN-AP1 to block Jnk/c-Jun or cJun shRNA, or SP6 can be co-treated in IκBαSR-expressing cells. If the end result of the
inhibitor and genetic inhibition is the same as two inhibitors, then I can conclude that the
effects I observe are due to direct interactions. I performed these experiments in WT and
Tnfr-/- LCs expressing IκBαSR treated with or without SP6 (Figure 40A), WT LCs
expressing DN-AP1 treated with or without BAY (Figure 40B), and WT LCs expressing
c-Jun shRNA treated with or without BAY (Figure 40C). In each case, the genetic
modification augmented the inhibitor’s effects. This suggests that the effects I observe
with the combination drug therapies are specific, and not due to off-target effects. Cells
expressing empty vector or scrambled shRNA (where appropriate) and treated with
vehicle were used as negative controls.
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Figure 40. Confirmation of inhibitor specificity in LCs

A) WT LC and Tnfr-/- LC were transduced with IκBαSR-GFP. GFP+ cells were sorted and
plated in methylcellulose with or without SP6 treatment. Values are normalized to vectoronly transduced control cells. B) LCs were transduced with DN-AP1-GFP. GFP+ cells
were sorted and plated in methylcellulose with or without BAY treatment. C) LCs were
transduced with c-Jun-shRNA1; GFP+ cells were sorted and plated in methylcellulose
with or without BAY treatment. shSCR transduction was used as control. Values shown
are mean ± SD from three independent experiments. * indicates p<0.05 as determined by
Student’s t test when compared to vehicle treated vector-expressing control cells. #
indicates p<0.05 when compared to indicated experiment groups as determined by
Student’s t test.

	
  

115	
  

	
  

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
To study whether combination treatment using both NF-κB and JNK signaling
inhibitors is also additive in eliminating human LC, I compared the responses of human
AML cell lines to the treatments. By incubating the LC with NF-κB and JNK inhibitors
individually or in combination for 12 hours, and then seeding for CFU to examine the
reduction of clonogenic LC, I observed additive inhibition effects of the two inhibitors in
almost all AML cell lines (Figure 41A). I noted that the sensitivity of AML cell lines to
such additive inhibition effects are correlated to levels of TNF expression (Figure 19D).
Cell lines RS4:11 (B-ALL), K562 erythroid LC and ML-2 that had a reduced response
also express lower levels of TNF, whereas the TNF-expressing cell lines, including HL60 (M2/3), ML-2 (M5), Molm-13 (M5), U937 (M5), NB4 (M3), and THP-1 (M5),
showed exceptional sensitivity to the combined inhibitor treatment. Results shown are
normalized to colonies formed by vehicle-treated cells.
The most sensitive human AML cell lines to the combination therapy showed
constitutive NF-κB activity, as determined by p65 localization to the nucleus, while the
least sensitive cell lines did not have constitutive NF-κB activation (Figure 41B). In
addition, I found that, although all the sensitive cell lines showed TNF-stimulated NFκB-independent JNK-c-JUN activation (Figure 41C), the most sensitive AML cell lines
(U937, NB4 and THP1) had increased basal levels of NF-κB and JNK-c-JUN activities as
shown by elevated nuclear p65 and total p-JNK/p-c-JUN. Vehicle-treated cells were used
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Figure 41. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human
AML cell lines

A) CFU from human leukemic cell lines treated with indicated doses of SP, BAY or
combination. Results shown are mean ± SD from three independent experiments. *
indicates p<0.05 when compared to vehicle treated control, as determined by Student’s t
test. # indicates p<0.05 when compared to indicated experiment groups as determined by
Student’s t test. B) Nuclear fractionation analysis showing NF-κB activity in AML cell
lines. Results shown are representative of three independent trials. C) Several TNF-high
expressing AML cell lines were treated with TNF and BAY individually or in
combination. Levels of p-JNK and p-cJUN were examined by Western blotting. Results
shown are representative of three independent trials.
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as negative controls, and protein levels were normalized to α-Tubulin/Lamin (Figure
41B) or GAPDH (Figure 41C) as loading control.
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing primary
AML patient samples
The gold-standard of testing novel drug efficacy is to use tumor samples excised
directly from newly-diagnosed patients. I collaborated with the clinicians at the
hematology oncology department at Loyola University Medical Center to collect
peripheral blood and bone marrow aspirate samples from newly diagnosed AML patients.
Upon receipt of these samples, nucleated cells were purified using Ficoll-paque
centrifugation and cultured as stated in the methods section. In healthy patients, colonyforming cells are rarely found in the peripheral blood, so I used Peripheral Blood Stem
Cells (PBSCs) isolated from donors following G-CSF therapy to mobilize HSCs from the
niche for collection.
I found that while all but one sample were somewhat sensitive to combined NFκB and JNK inhibition, 3/6 were highly sensitive with CFU reductions of >80%. Two of
these samples expressed high levels of Tnf, while the third did not. At the time I proposed
that this sample (patient #6) may express high levels of IL1. This has since been
confirmed (Figure 42).
These data, taken together suggest that some AMLs use TNF as an autocrine
survival signal by activation of JNK as a pro-survival/proliferation marker. AMLs also
use secreted TNF as a paracrine signal to reorganize the niche and eliminate HSPCs,
which use JNK as a pro-death signal (Figure 42 model).
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Figure 42. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing
primary AML patient samples

Mononuclear cells from AML patient samples isolated from the peripheral blood were
isolated and cultured overnight in patient sample medium. 1x104 live cells were plated in
methylcellulose along with indicated treatments and read for CFU assay. Remaining cells
were lysed and RNA isolated for qRT-PCR. Results shown are normalized to vehicle
treated cells, and are mean ± SD from three independent trials. * indicates p<0.05 when
compared to vehicle treated cells, # indicates p<0.05 when compared to indicated
experiment groups, and ~ indicates p<0.05 when compared to TNF mRNA levels of
PBSCs, all determined by Student’s t test.
Figure 42 model.
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Aim 2. Determine IL1 contribution to TNF-independent, NF-κB independent
survival and chemoresistance of LSCs to NF-κB inhibition.
IL1 stimulates Jnk and Jun family members’ activation in LCs
When I saw that some patient samples that do not express TNF were sensitive to
NF-κB and JNK inhibition treatments, I suggested there might be additional proinflammatory cytokines operating similarly to TNF, but in a parallel fashion. This would
account for some of the AML patient samples that responded to NF-κB and JNK
inhibition, but did not express TNF. To find out which pro-inflammatory cytokines could
be producing such an effect, I turned to the resources available by my collaborators. They
determined that the same patients that express high levels of TNF also express high levels
of IL1 (Figure 3). My collaborators also found that LSCs, in addition to producing
endogenous IL1, respond to exogenous IL1 stimulation by promoting survival and
proliferation (Figure 4). I confirmed that the mouse MLL-AF9 LCs produced both Tnf
and IL1 by western blot analysis by looking at tumors isolated from three separate
xenograft transplants of LCs into mice (Figure 43A). If IL1 was operating in parallel to
TNF, then I would expect to see activation of JNK and subsequent Jun family members.
To test this, I stimulated LCs with exogenous IL1 and Tnf and measured the
phosphorylation events on Jnk, c-Jun, and JunB. I found that while Tnf is a strong
inducer of Jnk and c-Jun, IL1 is a weak inducer of Jnk and c-Jun. JunB was equally
activated by both Tnf and IL1 (Figure 43B). This suggests that without Tnf, LCs are able
to secrete IL1 to activate similar signaling pathways. Therefore, blocking Tnf alone in
LCs will not be enough to inhibit NF-κB-independent survival.
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Figure 43. LCs produce IL1, which weakly activates Jnk, c-Jun, and JunB

A) LCs from three separate xenografts were isolated from mice, lysed, and analyzed for
Tnf and IL1 expression by western blot anaylsis. GAPDH was used as loading control.
Mature IL1 is the lower (strongest) band resolved, the upper band is non-specific. B) LCs
were stimulated with either Tnf of IL1 and contents were resolved for western blot
analysis. c-Jun phosphorylation can be determined by upward shift, and respective bands
are notated. GAPDH was used as loading control.
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c-Jun, JunB, and JunD contribute to LC resistance to NF-κB inhibition
When I screened through pro-inflammatory genes that were upregulated in AML
patient tumors, I found that the Jun family of proteins (c-Jun, JunB, JunD) were highly
expressed. While c-Jun is a well-described tumor promoter in most tissues studied, JunB
is widely considered to be a tumor suppressor.308 In order to understand the functions of
these proteins further, I did shRNA knockdown experiments and measured effects on
colony formation in LCs. I were able to stably knockdown each individual Jun family
member in LCs (Figure 44A). Total knockdown was compared to scrambled shRNAtransduced control, and protein loading was normalized to GAPDH, except for c-Jun
knockdown which was normalized to a non-specific band.
I found that knockdown of c-Jun resulted in a decrease in LC CFUs, but that JunB
knockdown resulted in a further decrease in CFUs, suggesting that JunB may be acting as
a tumor promoter parallel to c-Jun in these cells. JunD knockdown did not have a
significant effect on the CFU ability of LCs. However, blocking the entire family of
transcription factors with a c-Jun dominant negative (DN-AP1) had the most profound
effect on CFU reduction (Figure 44B). CFUs were normalized to vector/scrambled
shRNA controls.
When treated with NF-κB inhibitor (BAY), LCs expressing knockdown of any
Jun family member showed a significant decrease in CFUs when compared to vehicle
treatment. LCs expressing c-Jun shRNA were most susceptible to BAY treatment, but
both JunB and JunD knockdown had a significant decrease in colonies as well. The most
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Figure 44. Jun subunits c-Jun, JunB, and JunD contribute to LC survival and
resistance to NF-κB inhibition

LCs were transduced with indicated shRNAs. Knockdown was measured by western blot.
B) LCs expressing indicated shRNAs were plated in methylcellulose for CFU assay.
Results shown are relative to vector-expressing control. C) LCs expressing indicated
shRNAs were treated with BAY in methylcellulose for CFU assay. Results shown are
relative to vehicle-treated cells expressing each shRNA. * indicates p<0.05 when
compared to control (Vector in B, Vehicle in C), # indicates p<0.05 when compared to
indicated test groups, as determined by one-way ANOVA with Bonferonni post-hoc test.
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effective transgene was DN-AP1, suggesting that the different Jun family members might
contribute to certain degree of LC growth and are able to compensate for loss of another
(Figure 44D).
Jun family subunits cooperate to prevent differentiation in LCs
While knocking down each of the Jun family proteins, I observed that functional
repression of all family proteins of the AP1 family transcription factors (through
transduction with DN-AP1) resulted in a more significant effect and nearly complete
differentiation of LCs into granulocytes.
Because functional repression of all AP1 family of transcription factors resulted
in differentiation, I wanted to know which family member was responsible for blocking
differentiation. To study this in detail, I assayed the differentiation status of LCs with
each individual Jun family member knocked down. DN-AP1 drove complete
differentiation into granulocytes, as evidenced by mulit-nuclear morphology, stain
resistance, and cytoplasmic granule formation. Knockdown of each individual Jun family
member only induced partial differentiation the LCs, and failed to induce cytoplasmic
granule formation when compared to vector-transduced LCs (Figure 45, top row). I did
notice a proliferation defect in JunB-deficient cells, but did not investigate further.
Vector-transduced LCs were used as negative control.
I then found that knockdown of each Jun family member only resulted in a slight
decrease in cd117 surface expression (common stem cell marker for murine
hematopoietic cells, SCF receptor). However, functional repression of the entire family
resulted in complete loss of cd117 surface receptor, suggesting a more complete
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Figure 45. Jun family subunits cooperate to prevent differentiation in LCs

LCs were spinoculated with indicated constructs via retroviral transduction and plated in
suspension culture for 7 days. After this time, LCs were assayed for morphology by
cytospin followed by Wright-Giemsa stain. Differentiation is characterized by increase in
cytoplasm:nucleus ratio, change in counter-stain affinity (light purple vs. dark purple),
and presence of granules in the cytoplasm. Red scale bars indicate 20 µm. Additionally,
LCs were assayed for cd117 surface marker stain. Results shown are representative of
three independent trials.
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differentiation (Figure 45, bottom row). Surface receptor expression was compared to
vector control-expressing cells. Addition of vector did not change the cd117 levels
compared to untransduced cells. Taken together, these data suggest that multiple
members of the Jun family of transcription factors can compensate for each other.
TNF/IL1 inhibition sensitizes AML M4/5 to NF-κB inhibition
I determined, in murine AML models, that co-inhibition of pro-inflammatory
cytokines Tnf and IL1 can resensitize LSCs to NF-κB inhibition in vitro and in vivo.
I collected tumor samples from newly-diagnosed AML patients’ peripheral blood
or bone marrow at Loyola University Medical Center and isolated mononuclear cells by
Ficoll-Paque gradient centrifugation, and treated in methylcellulose culture with either
NF-κB inhibitor (BAY), combination of anti-TNF and anti-IL1 (Etanercept® and
Kinaret®), or all three together. I found that M0/1/2 (non-pro-inflammatory cytokineexpressing) were least susceptible, and combined treatment was not any more effective
than BAY alone. However, M4/5 AMLs (pro-inflammatory cytokine-expressing) and
non-classified AMLs generated secondary to therapy for other cancers were more
sensitive to the combination treatment (Figure 46). Results shown are normalized to
number of colonies grown in vehicle-treated patient samples. Further study is necessary
to determine the correlation of the effects of combined treated to TNF and IL1 expression.
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Figure 46. TNF/IL1 inhibition sensitizes AML M4/5 to NF-κB inhibition

BAY (100 nM)
anti-TNF (Etanercept® 25 ug/mL) + anti-IL1 (Kinaret®, 100 ng/mL)
BAY + anti-TNF + anti-IL1
Primary patient samples were collected and mononuclear cells isolated by Ficoll-Paque
gradient centrifugation, then cultured overnight in suspension culture. 1x104 live cells
were plated in methylcellulose containing the indicated treatments and colonies read 14
days later. Values shown are the % CFU normalized to vehicle treatment for each sample.
Horizontal bars represent mean ± SD. * indicates p<0.05 when compared to vehicle
treatment, # indicates p<0.05 when compared to indicated groups, both determined by
one-way ANOVA with Bonferonni post-hoc test.

	
  

	
  
	
  

CHAPTER 5
DISCUSSION
Increased NF-κB activity has been detected in a variety of types of human cancers
including nearly all types of hematopoietic malignancies.	
   However, mutations of the key
regulators of NF-κB signaling have been detected only in some B cell lymphomas and
multiple myeloma. In these B lymphocytic malignancies, abnormal activation of NF-κB
signaling is the result of active mutations of upstream regulatory components which are
less dependent on cytokine stimulation. Inhibition of NF-κB signaling in these
malignancies has been demonstrated to be an effective treatment option, inducing disease
remission and significant improvement in patient survival.318,319 In AML, there is
generally a lack of identified mutations in the components of NF-κB signaling,
suggesting enhanced NF-κB activity might be induced by micro-environmental factors.
Our studies suggest that TNF, produced by LC, promotes growth of these cells through
autocrine stimulation of NF-κB and JNK-AP1 as parallel proliferation/survival signals.
Therefore, the anti-leukemic effects of NF-κB inhibition in AML in vivo are likely
compensated by TNF activating anti-apoptotic genes operating through JNK.
Additionally, I showed that paracrine TNF released from LC represses the growth of
normal HSPC, suggesting a link to the hematopoietic repression observed in AML
patients. Therefore, I speculate that co-inhibition of both TNF-JNK and NF-κB signals
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might be a more comprehensive treatment for TNF-expressing AML by synergistically
repressing the growth of LC and simultaneously protecting HSPC. If this is the case, then
we would be able to eliminate LSCs in vitro by inhibiting NF-κB and TNF/JNK. To test
this, our collaborators performed an ex vivo treatment experiment where they treated LCs
with NF-κB inhibitor (BAY), JNK inhibitor (SP6), or Tnf mAB alone or in combination
before transplanting the surviving cell into mice. This kind of experiment allows us to
know if our treatment is toxic to leukemia initiating stem cells (LSCs). They determined
that indeed, blocking NF-κB and Jnk together was able to eliminate stem cells because
the tumors xenografted into mice were significantly delayed in forming diseases (Figure
47A). Additionally, they xenografted untreated LCs into mice and treated the mice
following engraftment. Blocking Tnf alone in vivo was able to extend survival of
xenograft mice, but not for a profoundly longer period of time (Figure 47B). This was
most likely due to IL1 acting in parallel, and unaffected by the Tnf blocking antibody
treatment. Therefore, we needed to block all downstream signaling by directly inhibiting
both NF-κB and Jnk together. To test this, our collaborators treated MLL-AF9 LCxenografted mice with either BAY or SP6 alone or in combination and found that the
combination treatment was very successful in prolonging survival in mice (Figure 47C).
These results prompted our investigation into Tnf-independent pro-inflammatory
signaling in LCs, and ultimately led us to IL1.
Our studies show that IL1 stimulation appears to functionally similar and parallel
to Tnf stimulation in LCs. This suggests that these two pathways can be activated and
compensate for NF-κB inhibition in LCs. To test this hypothesis, I inactivated both Tnf
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Figure 47. Co-inhibition of NF-κB and Jnk eliminates LSCs in vitro and in vivo

A) LCs purified from mice were plated in suspension culture, and treated for 12 hours.
Following treatment, 2x103 live cells were isolated and transplanted back into lethallyirradiated transplant mice. 5 mice were used for each group. B) 2x104 LCs were engrafted
for 20 days in sub-lethally irradiated mice. After engraftment, mice were treated with
indicated treatments every other day for 10 days. C) 2x104 LCs were engrafted for 20
days in sub-lethally irradiated mice. After engraftment, mice were treated with indicated
treatments every other day for 10 days. Mice received BAY (10 mg/kg IP), SP6 (30
mg/kg IP), alone or in combination. Single treatment survival was significantly enhanced
when compared to vehicle-treated mice, and combination treatment survival was also
significantly enhanced. * indicates p<0.05 when compared to vehicle survival by LogRank test, ~ indicates p<0.05 when compared to BAY treated mice by Log-Rank test.
These experiments were performed by collaborators Drs. Jing Li and Xinyu Li at
Shanghai Normal University, Shanghai, China
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and IL1 signaling through either pharmacologic inhibition of the ligand or genetic
inactivation of the receptors through knockout or knockdown, followed by treatment with
NF-κB inhibitor (BAY).
Inhibition of Tnf or IL1 using anti-TNF and IL-1Ra in combination with BAY
was significantly better at reducing CFUs in LCs than single treatment of any one
compound (Figure 48A). Vehicle-treated LCs were used as negative controls. I
confirmed the specificity of the treatments by treating WT and Tnfr-/- LCs in parallel with
IL-1Ra and BAY. The Tnfr-/- LCs treated with IL-1Ra and BAY reduced CFUs at a
similar rate as WT LCs treated with anti-TNF, IL-1Ra, and BAY. This suggested that the
inhibition and effects of IL-1Ra were specific for IL1, and that anti-TNF was specific for
Tnf receptors (Figure 48B). Vehicle-treated cells from each genotype were used as
negative controls. Finally, I inactivated the IL1 signaling pathway by using an shRNA
specific for IL1 receptor. In these cells, inactivation of IL1 receptor via shRNA
synergized with anti-TNF and BAY in methylcellulose and significantly reduced the
CFU ability of LCs (Figure 48C). Vehicle-treated cells expressing scrambled shRNA on
a retrovirus were used as negative controls.
I proposed that LSCs secrete pro-inflammatory cytokines in order to promote
their own survival (autocrine effect) and to reorganize the niche to support themselves
(paracrine effect). This allows LSCs to protect themselves from NF-κB inhibition in vivo.
If this is indeed the case, then co-inhibition of both pro-inflammatory cytokines Tnf and
IL1 can re-sensitize transplanted mice to NF-κB inhibition in vivo. To test this my
collaborators performed two experiments: an ex vivo treatment and transplantation to
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Figure 48. IL1 receptor inactivation sensitizes LCs to NF-κB inhibition

A) WT LCs were treated with either IL-1Ra, anti-TNF, or BAY alone or in combination
as indicated in methylcellulose. Colonies were read seven days after treatment. B) WT
and Tnfr-/- LCs were treated with IL-1Ra or BAY alone or in combination, as indicated.
Colonies were read seven days after treatment. C) LCs expressing scrambled shRNA or
IL-1 shRNA were treated with anti-TNF or IL-1Ra alone or in combination in
methylcellulose. Colonies were read seven days following treatment. Results shown are
mean ± SD from three independent trials. * indicates p<0.05 when compared to vehicle
treated controls as determined by one-way ANOVA with Bonferonni’s post-hoc test.
These results were generated Dr. Jing Li at Shanghai Normal University, Shanghai,
China.
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determine if the treatment would eliminate LSCs, and in vivo engraftment and treatment
to determine if I could return the niche to its original anti-inflammatory state and
resensitize LSCs to NF-κB inhibition.
Ex vivo treatment of WT LCs with anti-TNF, IL-1Ra, or BAY alone or in all
combinations revealed that blocking one of any signal eliminated some LSCs in the in
vitro stage. Combination of any two treatments was better, and almost complete
elimination of LSCs was observed when all three signals (Tnf, IL1, and NF-κB) were
blocked ex vivo (Figure 49A). Vehicle treatment studies were used in parallel as negative
controls.
In vivo engraftment of leukemia followed by ten days of treatments with indicated
inhibitors showed similar results. However, in this model, single inhibition of Tnf, IL1,
and BAY was not nearly as effective as in the ex vivo experiment, suggesting LSCs use
both pro-inflammatory cytokines in parallel to reorganize the in vivo niche and promote
their own survival. However, combination therapy of all three factors (Tnf, IL1, and
BAY) was able to triple survival time of transplanted mice, and even induce complete
remission in some (Figure 49B).	
  
The in vivo engraftment and ex vivo treat-and-transplant studies suggest that
pharmacological inhibition of pro-inflammatory cytokines can resensitize LSCs to NF-κB
inhibitor treatment in vivo. I confirmed our inhibitor specificity by repeating the
experiments in Figure 49 using Tnfr-/- LCs instead of WT LCs and treating with
combinations of IL-1Ra and BAY. I confirmed that the Tnfr-/- LCs exhibit a significant
delay in leukemia formation when compared to WT LCs. Interestingly, ex vivo treatment
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Figure 49. Inhibition of IL1, Tnf, and NF-κB eliminates LSCs in vivo

A) WT LCs were treated ex vivo with indicated compounds (IL-1Ra: 500 ng/mL, antiTNF: 20 ug/mL, BAY: 150 nM) and live cells were transplanted into recipient mice. B)
LCs were transplanted into sub-lethally irradiated mice and allowed to engraft for. Mice
were treated every other day (IP injection) with indicated drugs (IL-1Ra: 100mg/kg, antTNF: 10 mg/kg, BAY: 10 mg/kg). Results are shown as % survival over time. * indicates
p<0.05 compared to vehicle treated control, ~ indicates p<0.05 compared to BAY-treated
group as determined by log-rank test.
Results obtained by Dr. Jing Li at Shanghai Normal University, Shanghai, China.
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of Tnfr-/- LCs with BAY + IL-1Ra prevented disease development in 6/8 transplant mice
(Figure 50A), which was better than 2/7 ex vivo-transplanted mice with WT LCs treated
with anti-TNF, IL-1Ra, and BAY (Figure 50A). This suggests that LSCs may have a
way to utilize Tnf-mediated signaling internally, or in a manner that cannot be blocked by
anti-TNF treatment during in vitro assays, but could also be due to the efficiency of
inhibition of the anti-Tnf antibody. Vehicle treated Tnfr-/- LCs were used as controls.
In vivo engraftment of Tnfr-/- LCs in sub-lethally irradiated mice treated
with IL-1Ra and BAY showed similar rates of survival to mice transplanted with WT LCs
and treated with anti-TNF/IL-1Ra/BAY (Figure 50B). This suggests that combined
inhibition of both pro-inflammatory cytokine signaling (Tnf and IL1) can remove the NFκB independent parallel survival signals and resensitize LSCs to NF-κB inhibition. Most
of these mice survived for approximately 100 days, which was comparable to mice
transplanted with WT LCs receiving the triple-inhibition treatment. Vehicle treated mice
transplanted with Tnfr-/- LCs were used as negative control.
In skin and liver tissues, TNF-induced tissue damage is primarily mediated by
JNK signals inducing apoptosis/necroptosis. Normally, TNF-induced damage in these
tissues is prevented by NF-κB. NF-κB signal inactivation results in severe inflammationrelated tissue damage due to the excessive sensitivity of signal-inactivated cells to TNFJNK-induced death signaling.287,289,290,320-324 The tumor-promoting effects of TNF in
these tissues are also mediated by JNK signaling through a “complementary
proliferation” and/or senescence repressing mechanisms.287,289,290,320-324 NF-κB functions
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Figure 50. Genetic elimination of Tnf receptors further sensitizes LSCs to IL1 and
NF-κB inhibition in vivo

A Tnfr-/- LCs were treated ex vivo with indicated compounds (IL-1Ra: 500 ng/mL, BAY:
150 nM) and 2x103 live cells were transplanted into lethally irradiated mice. B) Tnfr-/LCs were transplanted into sub-lethally irradiated mice and allowed to engraft for 20
days. Mice were treated every other day (IP injection) with indicated drugs (IL-1Ra:
100mg/kg, BAY: 10 mg/kg). Results are shown as % survival over time. * indicates
p<0.05 compared to vehicle treated control, ~ indicates p<0.05 compared to BAY-treated
group as determined by log-rank test.
Results were obtained Dr. Jing Li at Shanghai Normal University, Shanghai, China.
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as a tumor suppressor in these tissues by repressing TNF-JNK activity. Therefore,
blocking the TNF-JNK signal can largely repress both tissue damage and tumor
generation in NF-κB signal-inactivated animals. These studies provide a strong empirical
basis for our combination treatment approach consisting of inhibition of both signals
simultaneously. Doing so should not only enhance the anti-leukemic effects but may also
reduce the side-effects in other tissues usually induced by NF-κB inhibitors.
The two contradictory activities of TNF-JNK signaling, pro-death and prosurvival/proliferation, in normal/benign tissue cells and malignant cells have been
reported in other systems. In Fanconi’s anemia, JNK is required for TNF-induced
leukemic clonal evolution of Fancc-mutant HSPC by inducing apoptosis in mutant cells
and stimulating proliferation/survival activities in LC 279. In Drosophila, TNF represses
tumor growth of scribble (a tumor suppressor)-mutant cells by stimulating a JNKmediated death signal. However, via JNK, TNF promotes tumor progression and
metastasis in scribble-mutant cells when either oncoprotein RAS or Notch is
expressed.325 In skin epidermis, via the Tnfr1-Jnk2-Ap1 signaling pathway, TNF
promotes epidermal cell proliferation by up-regulating the cell cycle positive regulator
CDK4 and down-regulating cell cycle negative regulators such as P16Ink4a. Such signals
which prevent growth restraint and the induction of senescence are required for epidermal
neoplasia induced by NF-κB-inactivation, chemicals, UV irradiation or oncogenic
Ras.289,320,321 In hepatocytes, TNF-JNK induces apoptosis in large numbers of cells and
stimulates compensatory proliferation in remaining cells, which are required for chemical
or genetic lesion (such as Nemo deletion)-induced hepatocellular carcinoma.290,322-324
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These studies suggest that a combination of NF-κB and JNK inhibitors might also be
useful in the treatment of these cancers. However, in certain types of cancer cells, the
pro-survival activities of JNK might be dependent upon NF-κB signaling activity. In such
cells, inactivation of the NF-κB signal will convert the pro-survival activity of JNK
signaling to pro-death activity.326 Therefore, to best use such combination treatment in
cancer therapy, it is important to distinguish whether or not the pro-survival/proliferative
activity of JNK is NF-κB signal dependent.
Evidence also suggests that whether a cell undergoes death or
proliferation/survival fate in response to TNF-JNK signaling is determined by the
duration of JNK activity. Elongated JNK activity (>2 hours) induces cell death (as shown
in HSPC), whereas limited JNK activity (<2 hours) promotes cell proliferation/survival
(as shown in LC). I found that the duration of JNK in murine LC is primarily limited by
MPK5 which is independent of NF-κB signal. Thus experiments to determine whether
expression of MKP5 is elevated in primary human LC will be necessary in future studies.
Such studies will allow us to evaluate if inactivation of MKP5 could be a treatment for
AML patients.
The inflammatory reaction has been described as a very important component of
the tumor environment in many solid tumors. In these tumor tissues, chemokine(s)
secreted by malignant cells induce(s) the infiltration of many types of
hematopoietic/immune cells (such as macrophages, myeloid-derived suppressor cells, NK
cells and T/B-lymphocytes) to the tumor tissues. Most of the tumor-infiltrating
hematopoietic/immune cells stimulate a persistent cycle of damage and repair in tumor
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tissue to generate a tumor-promoting inflammation by producing tumor supporting
cytokines including TNF, IL-1, and IL-6. Thus, such cells and the inflammatory
cytokines and signals generated by them have been proposed to be critical targets for
anti-tumor therapy.244,251,256,282,327-332 However, almost all of the previous studies evaluate
the anti-tumor activity by targeting these cytokines and their signaling pathways
individual. In fact, signals stimulated by these cytokines are not independent. Most of
these cytokines share some common signaling pathways and function compensatory.
Thus inactivation one cytokine stimulated signaling most case is not sufficient to repress
tumor growth due to the compensation of signaling stimulated by other cytokines. Our
studies suggest that removing all the tumor promoting cytokines might be necessary for
maximally eliminating tumor cells especially for tumor stem cells.
I found that the expression of TNF and IL1 are elevated in many M4/M5 subtypes
of AML cells. Early studies suggested that IL1 is an autocrine survival factor in many
types of AML cells. Also, significantly elevated IL1 levels in serum of many AML
patients and are correlated to poor prognosis. IL1 promotes the colony forming ability of
AML cells333,334 by stimulating the activation of downstream signaling and/or the
secretion of hematopoietic cytokines such as GM-CSF in AML cells and stromal
cells.330,331,335 By blocking these pro-inflammatory cytokines, IL1 antagonists, sIL-R or
IL-1Ra repress the growth and CFU of AML cells in a dose-dependent fashion.336-338
Recent studies demonstrated that IL1RAP, a well-known coreceptor of IL-1R1 is highly
expressed in many AML patient samples339,340 and might be involved in LSC selfrenewal.336,337,338,339 In addition, elevated phospho-IRAK1, a hallmark of activated IL1
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signaling, was detected in advanced MDS and AML patient samples, which has also been
described as an anti-AML target. However, the role of IL-1 in AML development and
progression in vivo have not been evaluated.
This production of pro-inflammatory cytokines is most likely caused by the driver
mutations (fusion genes, chromosomal deletions, or other point mutations) because nontransduced/transformed HSPCs do not produce such cytokines. Once one of these driver
mutations is introduced into the HSPCs do pro-inflammatory cytokine production and
secretion begin. Additionally, one of the major functions of NF-κB is to drive proinflammatory cytokine production. By relying on NF-κB, LSCs need to find a way to at
least compensate for the pro-death signals generated by TNF and IL1. My studies show
that LSCs not only compensate, but can capitalize on these pro-inflammatory cytokines
due to activities of JNK and nuclear substrates from the AP-1 family.
We found that treatment of LCs with a TNF blocker was not sufficient to sensitize
these cells to NF-κB inhibition. This could be due to two different mechanisms: (1) there
are additional pro-inflammatory cytokines being produced that can function parallel to
TNF, and (2) TNF and its receptor are synthesized by the same cells, allowing for both
receptor and ligand to be present inside the same sorting vesicle following synthesis by
the Golgi. I was able to account for the first option in this dissertation by screening for
additional pro-inflammatory cytokines. However, the second option is also possible. This
may be why the anti-TNF mAB treatment did not work in vitro when the cells are
sufficiently spread out enough to prevent paracrine signaling. By expressing both TNF
and its receptor on sorting vesicles as they travel from Golgi to the cell surface, LSCs can
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benefit from TNF signaling without having to utilize anything at the cell surface. This
type of intracellular signaling was shown in 2005 using HEK 293 cells transduced with
different mutant versions of TNF receptors.341
Similar to TNF, IL-1 stimulates the activation of JNK and NF-κB signaling. A
balance of JNK and NF-κB signaling is absolutely required for the proper response of
normal tissue cells to pro-inflammatory cytokine-stimulated reactions. Inactivation of
NB-κB signaling results in cell death-related damage and compensatory proliferation in
most tissues due to the excessive response of tissue cells to inflammatory cytokinestimulated JNK signaling. JNK induces a pro-apoptotic activity in most normal tissues
which can be converted into pro-survival/proliferation signaling by oncogenic
mutation(s), thereby promoting tumor development and progression. I found that most
tumors from all AML subtypes (M0-M7) express some degree of IL1, M4 and M5 subtypes of AML are particularly highly pro-inflammatory as shown by increased IL1 and
TNF expression. Here, I report that combined inhibition of JNK and NF-κB signaling
might be a better treatment for TNF-expressing AML, but I further demonstrated that
such therapy might also represent an useful therapeutic strategy for IL1 expressing AML.
Although our in vitro study suggested that the TNF/IL1 low-expressing AML cells
respond less to JNK and NF-kB inhibitor treatment, I predict that our combined inhibitortreatment might be also benefit to these AML patients when combined with canonical
chemotherapies. I found many TNF/IL1 low-expressing AML samples express Toll-like
receptors (TLRs) including TLR2, 4 and 5 (Cannova et al unpublished data). The TLRs
in AML cells can be activated by pathogen-associated molecular patterns (PAMPs)
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during bacterial/viral infections and damage-associated molecular patterns (DAMPs)
released by the dead cells during chemotherapy. Activated TLRs can stimulate JNK/NFkB directly through MyD88-mediated pathway and/or indirectly by stimulating the
production of inflammatory cytokines. Additionally, TNF and IL-1 can be produced by
bone marrow niche cells and other tissue cells especially during chemotherapy or
irradiation therapy or during AML LSC reorganization of the hematopoietic niche. This
pro-inflammatory niche environment plays a critical role in leukemia drug-resistance by
protecting LSCs from chemotherapy. Whether or not TNF/IL1 induced JNK/NF-kB
signaling contribute to drug-resistance development need to be further verified.
In this study, I also identify that multiple Jun family members can compensate for
loss of others. This is in contrast to the classic belief that c-Jun functions primarily as a
tumor promoter while JunB functions as a tumor suppressor. Knockdown of individual
family members of the AP1 transcription factors (c-Jun, JunB, and JunD) can each induce
a reduction in CFU ability in LCs and can sensitize such cells to NF-κB inhibitor
treatment. However, the best response is observed when the entire family is blocked
through transduction with DN-AP1, which can bind with Fos and other AP1 family
members, be phosphorylated by Jnk, but cannot bind to DNA because it lacks the DNAbinding domain. Only DN-AP1 can completely differentiate and sensitize LCs to NF-κB
inhibitor, suggesting that multiple family members of Jun can compensate for loss of any
other. This also suggests that JunB and JunD can function as tumor promoters in AML.
Multiple NF-κB inhibitors such as proteasome inhibitor Bortezomib and natural
compound Parthenolide have been successful used in clinical for Multiple Myeloma
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therapy and currently under evaluation in clinical trials for AML treatment in
combination with other canonical chemotherapy drugs.342,343 Unfortunately, clinical grade
JNK inhibitors are not available. However, I found that in these TNF/IL-1 expressing
AML, inactivation of JNK signaling can be achieved by co-inhibition of both IL1 and
TNF. Our studies suggest this will have a dual role: (1) it will represses the growth of and
significantly sensitize clonogenic leukemic progenitor cells and leukemogenic LSCs to
NF-kB inhibitor treatment, and (2) protect healthy HSPCs from chemotherapeutic
intervention and assist them in recreating a healthy niche microenvironment. Given that
both TNF and IL-1 antagonists are commonly used in clinical for rheumatoid arthritis and
autoimmune diseases and are confirmed safe, I speculate that I might able to use these
FDA approved TNF/IL1 antagonists and NF-κB inhibitors to evaluate our novel
treatment approach in AML patients.
In addition, oral and intestinal mucositis are severe pathologic conditions
afflicting most patients treated with standard chemotherapy or radiation therapy.344-348	
  
TNF and IL1-stimulated inflammation has been determined as the perpetrators for such
side effects. In addition, TNF/IL-1 might be also contribute to the leukemia-promoting
pro-inflammatory microenvironment by inducing MRD survival and drug-resistance.349
In AML patients, combined chemotherapy together with TNF/IL-1 antagonizes and NFκB inhibitor might be benefit leukemia patients by preventing the severe intestinal side
effects and might be also help to eliminated MRD.
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Future Directions
In this dissertation, I have provided evidence and support for treating AML with
anti-inflammatory drugs (anti-TNF, anti-IL-1) in combination with NF-κB inhibition.
The LSC niche is more critical for maintaining leukemia tumors during chemotherapies
than for leukemia development, because LSCs have been isolated in niche-independent
environments including the peripheral blood. For future studies, I would like to focus on
how the LSC niche provides protection to LSCs by sheltering them during chemotherapy.
To test this, I would label LCs and engraft these cells into sublethally-irradiated recipient
mice, treat with chemotherapeutic agents, and perform experiments isolating factors of
the LSC niche that support these cells. I know that a subset of cells will remain following
therapy and reconstitute the tumor (MRD). These experiments will determine which
factors are required for supporting MRD via the niche, and will focus on cellular
components of reorganization like CAFs, TAMs, and vascular endothelia-supporting
AML cells.
Intracellular signaling of pro-inflammatory cytokines is something I find very
interesting. As a continuation of this project, I would propose to look at the ability for
LCs from different FAB subtypes of AML to signal in this manner. By blocking
intracellular signaling, we may find a new way of targeting LSCs.
Finally, all of the targets I identified as good anti-LSC therapies in this
dissertation are currently drugable using FDA-approved medications. These drugs
(Kinaret®, Etanercept®, and Velcade®) are available, well-tolerated by patients, and
have approved dose levels and schedules. In the future, I would like to propose a clinical
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trial and recruiting patients for treatment with TNF/IL1 blockers in combination with NFκB inhibition for M4/5 AML.
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